Cite this: RSC Adv., 2021, 11, 17116

Recent updates on the bioactive compounds of the marine-derived genus *Aspergillus*†

Raha Orfali,^a Mahmoud A. Aboseada,^b Nada M. Abdel-Wahab,^c
Hossam M. Hassan,^{ib} Shagufta Perveen,^{ib} Fuad Ameen,^f Eman Alturki^a
and Usama Ramadan Abdelmohsen^{ib}*^{cd}

The genus *Aspergillus* is widely distributed in terrestrial and marine environments. In the marine environment, several *Aspergillus* species have proved their potential to produce a plethora of secondary metabolites including polyketides, sterols, fatty acids, peptides, alkaloids, terpenoids and miscellaneous compounds, displaying a variety of pharmacological activities such as antimicrobial, cytotoxicity, anti-inflammatory and antioxidant activity. From the beginning of 2015 until December 2020, about 361 secondary metabolites were identified from different marine *Aspergillus* species. In our review, we highlight secondary metabolites from various marine-derived *Aspergillus* species reported between January 2015 and December 2020 along with their biological potential and structural aspects whenever applicable.

Received 19th February 2021
Accepted 9th April 2021

DOI: 10.1039/d1ra01359a

rsc.li/rsc-advances

Introduction

Of all marine-derived fungi, the genus *Aspergillus* has gained the most awareness since it accounted for about 31 percent of natural marine fungal products from 2010 to 2013.¹ Marine *Aspergillus* strains produce metabolites of different chemical structures, including fatty acids, polyketides, sterols, alkaloids, terpenoids, peptides, butenolides, and others, with a range of bioactivities, including antimicrobial, cytotoxicity, insecticidal, neuroprotective, and antioxidant activity. Plinabulin, a dehydrotetrapiperazine halimide analog, was terminated in phase II trials and also obtained a phase III review in 2015 for the treatment of non-small cell lung cancer (advanced metastatic) and now has become FDA-approved.^{1–3} Reviewing the available literature concerning the genus *Aspergillus* marine-derived metabolites, a study was found demonstrating the

bioactivities and chemical structures of 512 marine metabolites of *Aspergillus* origins between January 1992 and December 2014.¹ Herein, the present study surveys most of the bioactive principles isolated from the marine-derived genus *Aspergillus* from 2015 till December 2020 and their abundance along with pharmacological potential.

Pharmacological activities

Over 5000 bioactive compounds have been identified from marine sources over the last few decades, showing various biological activities, including antibacterial, antitumor, anticoagulant, antifungal, anti-inflammatory and antiviral activities.^{4,5} Many of these metabolites are documented for their exceptional potencies that could be due to the need to resolve dilution of allelochemicals in seawater.^{6,7} Natural products extracted from marine *Aspergillus* spp. have been primarily linked to antimicrobial and cytotoxic bioactivities.⁸

Anticancer activity

Violaceimides A–B (1 and 2), two methylsuccinimide-based sulfur-bearing compounds, were isolated from *Aspergillus violaceus* WZXY-m64-17, a sponge-associated fungal strain. Both compounds exerted selective inhibition against the human leukemia U937 growth with IC₅₀ values of 5.3 ± 0.4 and 1.8 ± 0.6 μM, respectively and also against human colorectal cancer cell HCT-8 with IC₅₀ values of 1.5 ± 0.28 and 2.51 ± 0.51 μM, respectively.⁹

An enzyme with anticancer potential named L-asparaginase (LA) was purified and characterized from the marine-derived *Aspergillus niger*. This enzyme displayed impressive

^aDepartment of Pharmacognosy, College of Pharmacy, King Saud University, P. O. Box 22452, Riyadh 11495, Kingdom of Saudi Arabia. E-mail: rorfali@ksu.edu.sa; shakhan@ksu.edu.sa; emalturki@ksu.edu.sa

^bDepartment of Pharmacognosy, Faculty of Pharmacy, Nahda University, Beni-Suef 62513, Egypt

^cDepartment of Pharmacognosy, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt. E-mail: usama.ramadan@mu.edu.eg; nada_abdelwahab07@yahoo.com; Fax: +20-86-2369075; Tel: +20-86-2347759

^dDepartment of Pharmacognosy, Faculty of Pharmacy, Deraya University, 61111 New Minia, Egypt

^eDepartment of Pharmacognosy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62513, Egypt

^fDepartment of Botany & Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia. E-mail: FuadAmeen@ksu.edu.sa

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra01359a

antiproliferative activity against different lines of cancer cells, including U87MG, A549, HepG2, bone marrow-derived chronic myeloid leukemia cells and JURKAT E6 with IC_{50} values of 0.399, 0.375, 0.204, 0.2 and 0.22 $U\ mL^{-1}$, respectively.¹⁰ Asperterreusine A (3), a dihydrobenzofuran derivative, was purified from *Aspergillus terreus* [CFCC 81836], a marine-derived fungus. This benzofuran metabolite was investigated for its cytotoxic activities against diverse human cancer cell lines (SW-480 HL-60, A-549, SMMC-7721, and MCF-7). It showed cytotoxicity against SW-480 and HL-60 cancer cell lines with IC_{50} values of 25.7 and 15.3 μM , respectively.¹¹

Highly oxygenated meroterpenoids namely, terreustoxin A (4) and terretonin (5), were isolated from the Antarctic fungus *Aspergillus terreus*. These meroterpenoids displayed a proliferation inhibition of Con A-induced murine T cells at the concentration of 10 μM .¹² A meroterpenoid, terretonin C (6), a halogenated furanone, rubrolide S (7) and a butenolide derivative, 5-[(3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-6-yl)-methyl]-3-hydroxy-4-(4-hydroxyphenyl)-2(5H)-furanone (8), were isolated from the *Aspergillus terreus* OUCMDZ-2739, after chemical-epigenetic culture with 10 mM trichostatin A (TSA). For rubrolide S (7) against K562 cells, butenolide derivative (8) against K562 and MCF-7 cells and terretonin C (6) against MCF-7 cancer cell line with IC_{50} values of 9.5, 13.0, 10.1 and 8.5 μM , respectively, cytotoxicity was observed.¹³

A cryptic 3,4-dihydronaphthalen-(2H)-1-one (1-tetralone) derivative, aspvacin B (9) and a xanthone, namely sterigmatocystin (10) were obtained from the marine-derived *Aspergillus versicolor* KU258497 co-cultured with the bacterium *Bacillus subtilis* 168 trpC2. Both metabolites were assessed for their cytotoxic activities, showing moderate ($IC_{50} = 22.8\ \mu M$) for aspvacin B (9) to strong cytotoxic activity ($IC_{50} = 2.2\ \mu M$) for xanthone derivative (10) against the mouse lymphoma cell line L5178.¹⁴

Marine-derived fungus *Aspergillus terreus* extract was subjected to a chemical study yielding two butenolide derivatives, named (+)-3',3'-di-(dimethylallyl)-butyrolactone II (11) and versicolactone B (12). The two butenolides were evaluated against HCC1806, PANC-1, HepG2, HT-29 and BEAS-2B cancer cell lines, exhibiting potent cytotoxic activity against PANC-1 cancer cell line, with IC_{50} values of 5.3 and 9.4 μM , respectively. Morphological features of apoptosis were observed in 11 and 12-treated PANC-1 cells, including membrane blebbing, apoptotic body formation, nuclear condensation and cell shrinkage. Analysis of the cell cycle using propidium iodide staining showed that (+)-3',3'-di-(dimethylallyl)-butyrolactone II (11) inhibits the proliferation of PANC-1 cells through the S phase and G2/M arrest induction, while versicolactone B (12) could inhibit the induction of PANC-1 cells through the S phase arrest. Treatment with both metabolites substantially induced apoptosis of PANC-1 cells indicated by flow cytometric study.¹⁵

Fermentation of the mangrove-derived fungus *Aspergillus* sp. AV-2 on solid rice medium followed by chemical investigation led to the purification of prenylated benzaldehyde derivatives, named tetrahydroauroglauconin (13), isotetrahydroauroglauconin (14), isodihydroauroglauconin (15), flavoglauconin (16) and 2-(2',3'-epoxy-1',3',5'-heptatrienyl)-6-hydroxy-5-(3-methyl-2-butenyl)

benzaldehyde (17). All of them were assessed for their anti-proliferative activity against Caco-2 cell lines, exhibiting strong inhibition, where flavoglauconin (16) revealed the most potent cytotoxicity with IC_{50} of 2.87 μM .¹⁶ A biphenyl derivative, diorcinol (18) and an anthraquinone, versicolorin B (19) were isolated from a marine-derived fungus *Aspergillus versicolor* ZZ761. These compounds had anti-proliferative activity against human U251 and glioma U87MG cells with IC_{50} values of 6.2 and 4.4 μM and 30.5 and 11.3 μM , respectively.¹⁷

From the deep-sea-derived fungus *Aspergillus candidus*, *p*-terphenyl derivatives were isolated, namely terphenyllin (20) and prenylterphenyllin (21). The two metabolites were tested for *in vitro* antitumor activities, showing potent anti-proliferative effect against four cancer cells of Eca-109, Hela, PANC-1 and Bel-7402, with IC_{50} values varying between 5.5 μM and 9.4 μM .¹⁸ 3,4-Dimethoxyphenyl α -D-ribofuranoside (22), a phenolic glycoside, together with four indole-diketopiperazine alkaloids, namely echinulin (23), tardioxopiperazine B (24), neochinulin D (25), and varicolorin O (26) and nucleotides named uracil (27) and adenine (28), were isolated from the marine-derived endophytic fungus *Aspergillus amstelodami* (white beans culture). The antimelanogenic activity of the compounds isolated has been investigated. In B16 melanoma cancer cells, these compounds selectively repressed melanin output (arbutin was used as a positive control). Their IC_{50} values were 30.8 ± 5.57 (22), 38.5 ± 6.08 (23), 52.6 ± 6.64 (24), 98.0 ± 1.16 (25), 100.4 ± 3.05 (26), 112.0 ± 0.22 (27) and $144.7 \pm 2.35\ \mu M$ (28), respectively, compared to $151.7 \pm 1.27\ \mu M$ for arbutin.¹⁹

Epicoccolides A, B (29, 30) and NC3B (31), three polyoxygenated polyketides, were purified from *Aspergillus micronesiensis*, a marine-derived fungus *via* combined chromatographic methods. The three compounds were evaluated for their cytotoxic activity against LU-1, Hep-G2 and Vero cells, displaying significant cytotoxic bioactivities with IC_{50} values ranging between 3.97 and 4.71 $\mu g\ mL^{-1}$ (the IC_{50} values of the positive control, ellipticine = $0.29-0.31\ \mu g\ mL^{-1}$).²⁰ A diphenyl derivative, geodin (32) was isolated from *Aspergillus* sp. derived from the soft coral *Sinularia* sp. This metabolite has been tested for its cytotoxic activity against different lines of human cancer cells, including NCI-H460 large cell lung cancer cells, BT474 breast cancer cells, K562 chronic myelogenous leukemia cells, H-1975 non-small cell lung cancer cells, A549 lung cancer cells and DU1455 prostate cancer cells. Geodin (32) displayed substantial cytotoxic activity with IC_{50} values of 9.22, 8.88, 11.14, 9.96, 11.05 and 14.44 μM , respectively, against all cancer cells (positive control was staurosporine).²¹ A xanthone named AGI-B4 (33) was obtained from a deep sea-derived fungus *Aspergillus sydowii* C1-S01-A7. This xanthone remarkably exhibited selectively cytotoxic activity against A549 cell line with low IC_{50} value ($<10\ \mu M$) and the strongest cytotoxic activities for both HepG2 and A549 with IC_{50} values of 30.7 ± 0.9 and 8.1 ± 1.3 , respectively.²² Seco-anthraquinone, chlorotrypacidin (34), was isolated from *Aspergillus versicolor*, a gorgonian-derived fungus, the South China Sea. Chlorotrypacidin (34) displayed cytotoxic activity against various tumor cell lines HL-60, HCT-116 and HepG2, with IC_{50} values of 18.5, 17.6 and 15.2 μM , respectively.²³

Seven prenylated *p*-terphenyls, prenylterphenyllins F-J (35-39) and prenylcandidusins E and G (40, 41) were isolated from

a mangrove endophytic fungus, *Aspergillus candidus* LDJ-5. All these compounds are cytotoxic against SH-SY5Y, MGC-803, HCT-116, BEL-7402, A549, L-02, HeLa and U87 cells, with values in the IC₅₀ range between 0.4 and 24.4 μM .²⁴ A bis-indolyl benzenoid, petromurin C (**42**), was purified from the *Aspergillus candidus* KUFA0062 marine fungus (culture extract) derived from the marine sponge *Epipolasis* sp. Petromurin C (**42**) caused premature autophagy followed by apoptosis *via* mitochondrial stress concomitant with the intrinsic cell death activation pathway and Mcl-1 downregulation in FLT3-ITD mutated MV4-11 cells. Beside, petromurin C (**42**) was synergized with gilteritinib (FLT3 inhibitor clinically used) at subtoxic concentrations.²⁵

Prenylxanthones, A (**43**), C (**44**) and F (**45**), aspergixanthones, were isolated from the marine fungus *Aspergillus* sp. ZA-01. These prenylxanthones were evaluated for their cytotoxic activity. Aspergixanthones A (**43**) and F (**45**) demonstrated cytotoxicity against the neural cell line A-549 with IC₅₀ values of 1.8 and 1.1 μM respectively. Aspergixanthones C (**44**) and F (**45**) showed broad-spectrum cytotoxicities against five tumor cell lines, MDA-MB-231, MCF-7, MGC-803 and HeLa A-549, with values (IC₅₀) ranging from 1.1 to 9.8 μM .²⁶ Five prenylated indole alkaloids, 17-O-ethylnotoamide M (**46**), (–)-notoamide B (**47**), notoamides C (**48**) and M (**49**), and sclerotiamide (**50**), were isolated from of marine-derived fungi *Aspergillus sulphureus* KMM 4640 after co-culturing with *Isaria felina* KMM 4639. Notoamide M (**49**) caused the most inhibition against human prostate cancer cells 22Rv1 (colony formation) at a non-cytotoxic concentration of 10 μM , whilst other alkaloids caused inhibition at 100 μM .²⁷

An indole alkaloid, misszrtine A (**51**), was isolated from marine sponge-derived fungus *Aspergillus* sp. SCSIO XWS03F03. It demonstrated a strong antagonistic action on the cancer cell lines of the HL60 leukemia (IC₅₀ = 3.1 μM) and LNCaP prostate (IC₅₀ = 4.9 μM), implying that the functional group on misszrtine A (**51**) indole nitrogen has a significant impact on its cytotoxicity, which offers a means of understanding the structure–activity relationship.²⁸

A diketopiperazine alkaloid, mactanamide (**52**), was isolated from the marine sponge *Stylissa* sp.-derived fungus *Aspergillus flocculosus* collected in Vietnam. The isolated compound was evaluated for anti-proliferation activity, and a powerful effect of non-cytotoxic suppression on osteoclast differentiation was shown. Such suppression effects were demonstrated by osteoclast differentiation-induced receptor activation of the nuclear factor κB ligand (RANKL).²⁹ Chrysophanic acid anthraquinone (**53**), together with four bis-indolyl benzenoids, asterriquinol D dimethyl ether (**54**), kumbicin A (**55**), D (**56**) and (3*S*,6*S*)-3,6-dibenzylpiperazine-2,5-dione (**57**), were isolated from the cultures of *Aspergillus candidus* KUFA 0062, a marine sponge-associated fungus. These compounds were tested against several cancer cell lines for cytotoxicity: T98G, U-251, HCT116, A549, A 375, MCF-7, HT29 and HepG2, demonstrating cytotoxicity against all cancer cell lines tested.³⁰

Versixanthones N–O (**58**, **59**), two tetrahydroxanthone dimers, were isolated from *Aspergillus versicolor* HDN1009 (mangrove-derived fungus). These dimers exhibited extensive

cytotoxicities against different cancer cell lines (K562, HL-60, HO-8910, MGC803 and H1975), with IC₅₀ values ranging between 1.7 μM and 16.1 μM .³¹

An aspochalasin, tricochalasin D (**60**) has been isolated from the *Aspergillus* sp. found in the gut of *Ligia oceanica*, a marine isopod. It was evaluated for cytotoxic effect against prostate cancer cell line (PC3), showing strong activity with IC₅₀ value of 11.14 μM .³²

Cordylol C-3-O- α -D-ribofuranoside (**61**), 7-ethyldiorcinol (**62**), 3-hydroxydiorcinol (**63**), glyceryl diorcinolic acid (**64**), cordylol C (**65**), and aspergilol E (**66**), are six diphenyl ethers, which were purified from the marine-derived *Aspergillus sydowii* (ethyl acetate extract). These diphenyl derivatives were assayed for their cytotoxic effects against different cancer cell lines, including U937, 4T1, HT-29, PC3, HL-60, K562, A549 and NCI-H460, exhibiting selective cytotoxicity with IC₅₀ values varying between 3.36 ± 0.68 and 23.03 ± 1.345 against multiple cancer cell lines.³³ The initial fermentation of the fungus *Aspergillus ochraceus* cultivated from the Mediterranean sponge *Agelas oroides* on solid rice medium yielded a naphthoquinone derivative named viomellein (**67**) and phenylalanine derivative, namely ochratoxin B (**68**). These derivatives demonstrated a significant cytotoxic impact against human ovarian carcinoma (A2780) cells with IC₅₀ values of 5.0 and 3.0 μM , respectively.³⁴

Nine sesterterpenes, 14,15-dehydro-6-*epi*-ophiobolin K (**69**), 14,15-dehydro-ophiobolin K (**70**), 14,15-dehydro-6-*epi*-ophiobolin G (**71**), 14,15-dehydro-ophiobolin G (**72**), 14,15-dehydro-(*Z*)-14-ophiobolin G (**73**), 6-*epi*-ophiobolin C (**74**), ophiobolin C (**75**), 6-*epi*-ophiobolin N (**76**), and ophiobolin N (**77**), were isolated from *Aspergillus flocculosus*, a marine fungus originating from the seaweed *Padina* sp., Vietnam. For cytotoxic effect against various cancer cell lines, NUGC-3, HCT-15, NCI-H23, ACHN, MDA-MB-231 and PC-3, all isolated ophiobolins were investigated, showing potent cytotoxicities with GI₅₀ values varying between 0.14 and 2.01 μM .³⁵ Ochrazepines A–D (**78–81**), four circumdatin–aspyrone conjugates, were isolated from the coral-associated *Aspergillus ochraceus* strain LCJ11-102. Ochrazepine A (**78**) exhibited cytotoxic activity against numerous human cancer cell lines while ochrazepines B (**79**) and D (**81**) selectively inhibited the human glioblastoma U251 cell line and ochrazepines C (**80**) was active against the cell lines of human rhabdomyoma A673, human glioblastoma U87, and human liver cancer Hep3B, with IC₅₀ values of 2.5–11.3 μM .³⁶

A hydroxyl pyrrolidine derivative, preussin (**82**), was isolated from *Aspergillus candidus* KUFA 0062, a marine sponge-associated fungus. This pyrrolidine derivative was evaluated for its antiproliferative and cytotoxic effects in breast cancer cells (SKBR3, MCF7, and MDA-MB-231), and in MCF12A, a non-tumor cell line. Analysis of cell morphology for ki67 and caspase-3 was performed as well as 3D (multicellular aggregates) and 2D (monolayer) cultures tests, using various assays. This metabolite affected cell proliferation and viability in cultures of both 3D and 2D in all cell lines tested. 3D culture cells were less responsive and preussin-exposed cells morphological study revealed apoptosis, which was confirmed by caspase-3 immunohistochemistry.³⁷ In the course of chemical characterization of the marine-derived fungus *Aspergillus flavus*

Fig. 1 Chemical structure of compounds 1–21.

CF13-11, asperienes A–D (83–86), four C-6'/C-7' epimeric drimane sesquiterpenes, were isolated. These sesquiterpene esters displayed potent bioactivities towards various cell lines (MCF-7, HeLa, A549 and MGC-803) with the IC_{50} values ranging between 1.4 and 8.3 μ M. Moreover, compounds A (83) and D (86) demonstrated lower toxicity towards normal GES-1 cells than B

(84) and C (85), indicating greater potential for discovery as an antitumor candidate in the future.³⁸

A prenylated diphenyl derivative named dihydrobenzofuran diphenyl ether (87) was isolated from *Aspergillus tennesseensis*, a marine algae-endophytic fungus. It was examined for cytotoxic activities, displaying considerable *in vitro* inhibitory activity

Fig. 2 Chemical structure of compounds 22–39.

against the THP-1 leukemia cell line, with an IC_{50} value of $7.0 \mu\text{g mL}^{-1}$.³⁹ Nitrobenzoyl sesquiterpenes are rare from natural sources. 14-*O*-Acetylinsulicolide A (88), 6 β ,9 α -dihydroxy-14-*p*-nitrobenzoylcinnamolide (89) and insulicolide A (90), three nitrobenzoyl sesquiterpenoids, were isolated from the marine-derived fungus (*Aspergillus ochraceus* Jcma1F17). These

sesquiterpenoidal metabolites were evaluated for their cytotoxic effects against three various carcinoma cell lines, 786-O, ACHN and OS-RC-2, cells, displaying activities with IC_{50} values ranging between 0.89 and $8.2 \mu\text{M}$. In addition, 14-*O*-acetylinsulicolide A (88) induced late programmed 786-O cells death at

Fig. 3 Chemical structure of compounds 40–56.

a concentration of 2 μM (72 h treatment) and arrested the cell cycle at the G0/G1 phase at a concentration of 1 μM .⁴⁰

Based on the characteristics of the dimeric xanthone structures, three dimeric xanthones, versixanthones G (**91**), H (**92**)

and K (**93**) were isolated from the mangrove-derived *Aspergillus versicolor* fungus. These compounds showed the effects of Topo I inhibition and the most potent versixanthone G (**91**), a versixanthone H atropisomer (**92**), was assured of inhibiting Topo I-

Fig. 4 Chemical structure of compounds 57–73.

mediated DNA relaxation by targeting Topo I and thus stopping the cell cycle process and causing necrosis in cancer cells. Studies of molecular docking showed that versixanthone G (91) could bind DNA through π - π interaction and DNA Topo I *via* hydrogen bonds, forming a ternary complex.⁴¹ Ophiobolins, namely ophiobolins Z (94), K (95), O-Q (96–98), 21-*epi*-

ophiobolin Z (99), 6-*epi*-ophiobolin K (100), ophiobolin G (101), 21,21-*O*-dihydro-6-*epi*-ophiobolin G (102), were isolated from the mangrove fungus *Aspergillus ustus* 094102. These compounds displayed cytotoxicities against the HL-60, MCF-7, MD-MBA-231, MCF/Adr, A549 and G3K human cancer cells with the IC_{50} values ranging between 0.6 and 9.5 μ M.⁴²

Fig. 5 Chemical structure of compounds 74–88.

Chromatographic separation of the bioactive extract (anti-cancer) of the fungus *Aspergillus europaeus* WZXY-SX-4-1 derived from the marine sponge *Xestospongia testudinaria* has led to the isolation of various polyketide derivatives named

eurobenzophenone B (**103**), euroxanthone A (**104**), 3-de-O-methylsulochrin (**105**), yicathin B (**106**), dermolutein (**107**), and methylemodin (**108**). These polyketides were tested for the inhibitory effects toward the NF- κ B activation in SW480 human

Fig. 6 Chemical structure of compounds 89–104.

colon carcinoma cell line, displaying remarkable repression of NF- κ B expression in LPS-induced SW480 cells.⁴³ Two naphtho-c-pyrones, rubrofusarine B (109) and fansecinone A (110), were

purified from the marine-derived fungus *Aspergillus foetidus* KMM 4694. The effect of the substances on colony formation and viability of human drug-resistant prostate cancer cells

Fig. 7 Chemical structure of compounds 105–121.

(22Rv1) was evaluated, leading to induction of ROS production in these cells in cytotoxic concentrations (10.53% at 100 μM and 12.53% at 10 μM , respectively).⁴⁴ A naphthopyrone, namely

foncecinone C (111), was also isolated from the fungal strain *Aspergillus niger* 2HL-M-8 isolated from the mud sample, China (the intertidal zone, Huludao coastline). Foncecinone C (111)

demonstrated potent *in vitro* antiproliferative activity against cell lines A549, HL-60 and MGC-803.⁴⁵

The fungal strain *Aspergillus fumigatus* YK-7, which was cultivated from an intertidal zone collected from sea mud sample, China, yielded a terpenoid named pyripyropene E (**112**). This terpenoidal metabolite showed potent antiproliferative activity against U937, the human leukemic monocyte lymphoma cancer cells, with an IC₅₀ value of 4.2 μM .⁴⁶ Chemical investigation of the fungal strain *Aspergillus wentii* SD-310, isolated from the South China Sea (a deep sea sediment sample), yielded a tetranorlabdane diterpenoid named asperolide E (**113**). Cytotoxicity of asperolides E (**113**) was tested against a number of various cell lines, exhibiting cytotoxic activity against cell lines of human carcinoma of the cervix (HeLa), human breast carcinoma (MCF-7) and NCI-H446, with IC₅₀ values of 10.0, 16.0 and 11.0 μM , respectively.⁴⁷ A cytotoxic ester furan derivative (**114**) was isolated from the fungus *Aspergillus niger* obtained from the Northeast coast of Brazil (sediments). Cytotoxicity against HCT-116 (colon adenocarcinoma cell line) with IC₅₀ was demonstrated by the compound at 2.9 $\mu\text{g mL}^{-1}$.⁴⁸

For investigating the River Nile habitat, isolation of Di-(2-ethyl-hexyl) Phthalate (DEHP; **115**) from fungus *Aspergillus awamori* had been performed. DEHP showed cytotoxic activity against MCF7, HEPG2, HCT 116 and HELA cell lines with IC₅₀ values of 6.525, 26.73, 66.607 and 42.2958, respectively, concluding that the River Nile might be a tremendous resource for invention of bioactive metabolites.⁴⁹ All anticancer marine-derived *Aspergillus* metabolites are depicted in Fig. 1–7.

Antibacterial activity

Two anthraquinone dimers, namely 6,6'-oxybis(1,3,8-trihydroxy-2-((S)-1-methoxyhexyl)anthracene-9,10-dione) (**116**) and 6,6'-oxybis(1,3,8-trihydroxy-2-((S)-1-hydroxyhexyl)anthracene-9,10-dione) (**117**) were isolated from the marine-derived fungus *Aspergillus versicolor*. Both compounds displayed selective antibacterial activity against Gram-positive *Staphylococcus aureus* (30 μg per well).⁵⁰ Sponge-associated *Aspergillus* strain LS116 yielded a C23 steroid with bicyclo[4.4.1]A/B ring, namely aspergillsteroid A (**118**). This compound displayed significant anti-bacterial activity against *V. harveyi* with a MIC value of 16 $\mu\text{g mL}^{-1}$, demonstrating that aspergillsteroid A (**118**) could be considered one of promising agents for the aquatic disease control in the future.⁵¹

Chitosan polysaccharide was produced from unconventional sources, the marine-derived fungus *Aspergillus griseoaurantiacus* KX010988 by solid state fermentation of potato shells. Chitosan showed good antibacterial activity against *S. aureus*, *Bacillus subtilis*, and *Lactobacillus cereus* with inhibition zone diameter = 21 ± 0.81 , 19 ± 0.80 and 20 ± 0.71 , respectively by 40 μg per well.⁵²

Three analogues of citrinin, namely penicitrinone F (**119**), penicitrinol A (**120**) and citrinin (**121**), were isolated from the co-culture extracts of *Penicillium citrinum* EN-535 and *Aspergillus sydowii* EN-5344, two marine algal-derived endophytic fungal strains. The antimicrobial activity of the three compounds against *V. parahaemolyticus*, *M. luteus*, *Ed. ictaluri*, *V.*

alginolyticus and *E. coli* was evaluated, showing strong inhibition with IC₅₀ values varying from 4 to 64 $\mu\text{g mL}^{-1}$.⁵³ A meroterpenoid, terretonin G (**122**) was isolated from the *Aspergillus terreus* EN-539, marine algal-derived endophytic fungus. This meroterpenoidal metabolite showed inhibitory activity against *S. aureus* and *Micrococcus luteus*, with MIC values of 8 and 32 $\mu\text{g mL}^{-1}$, respectively.⁵⁴ Two aminobenzoic peptides, seco-clavatustide B (**123**) and clavatustide B (**124**) and a clavatoic acid derivative, 5-acetyl-2,4-dihydroxy-3-methylbenzoic acid (**125**), were characterized from the ascidian-derived endophytic fungus *Aspergillus clavatus* AS-107 (EtOAc extracts). The isolates were evaluated for various antimicrobial activities against aquatic and human pathogenic bacteria. Seco-clavatustide B (**123**) and clavatustide B (**124**) showed potent activity against *Pseudomonas aeruginosa* and *Aeromonas hydrophila* (aquatic pathogens) with MIC values of 8.8 and 8.2 μM , respectively. The clavatoic acid derivative (**125**) exhibited definite bacterial inhibitory activity against *M. luteus* with an MIC value of 38.1 μM .⁵⁵ An indoloditerpene, (3*R*,9*S*,12*R*,13*S*,17*S*,18*S*)-2-carbonyl-3-hydroxylemeniveol (**126**) was isolated from a marine-derived fungus *Aspergillus versicolor* ZZ761. This indoloditerpene showed antimicrobial activities against *Escherichia coli* with a MIC value of 20.6 μM .¹⁷

Five aromatic bisabolene-type sesquiterpenoid, named (7*R*,11*S*)-12 methyl hydroxylated sydowic acid (**127**), aspergoterpenin C (**128**), (7*S*,11*S*)-(+)-12-hydroxysydonic acid (**129**), (*S*)-(+)-11-dehydroxydonic acid (**130**), and engyodontiumone I (**131**) were isolated and characterized from the *Aspergillus versicolor* SD-330 fungus originated from deep-sea sediments. These compounds were tested for antimicrobial activities against aquatic and human pathogenic bacteria. Selective inhibitory activity against *E. coli*, *Aeromonas hydrophila*, *Vibrio harveyi* and *Edwardsiella tarda* zoonotic pathogenic bacteria was observed, in particular (7*R*,11*S*)-12 methyl hydroxylated sydowic acid (**127**), aspergoterpenin C (**128**) and engyodontiumone I (**131**), with MIC values ranging between 1.0 and 8.0 $\mu\text{g mL}^{-1}$.⁵⁶ A promising polyextremophilic marine fungus strain 8Na, known as *Aspergillus protuberus* MUT 3638, with the potential to produce antimicrobial metabolites, was isolated during the bioassay-guided method. Bisvertinolone (**132**), a sorbicillonoid, which was found to exhibit a major antibacterial activity against *S. aureus*, was identified as the active principle with a MIC 30 $\mu\text{g mL}^{-1}$.⁵⁷

Anthraquinone questin (**133**) from marine *Aspergillus flavipes* HN4-13 against *V. harveyi* (aquatic pathogenic) was investigated, in the basis of searching for the mechanistic pathway of its antibacterial activity. It exhibited favorable antibacterial and bactericidal activity against *V. harveyi* via disrupting the cell membrane and wall, which caused the destruction of integrity and permeability of cell membrane and wall, resulting in the intracellular biological components leakage and cell morphology change with MIC value of 31.25 $\mu\text{g mL}^{-1}$.⁵⁸ Antibacterial activities against various Gram-positive bacteria were seen in the *Aspergillus flavipes* DL-11 strain extract. Ten biphenyl ethers, namely 4'-chloroasterric acid (**134**), chloroasterrate (**135**), penicillither (**136**), iizukine A (**137**), asterric acid (**138**), monomethylisoic acid (**139**), butyl 2,4-dichloroasterrate (**140**),

2,4-dichloroasterric acid (**141**), methyl dichloroasterrate (**142**) and geodin hydrate (**143**), two benzophenones, named monochlorsulochrin (**144**) and dihydrogeodin (**145**) together with two xanthenes, methyl(2-chloro-1,6-dihydroxy-3-methylxanthone)-8-carboxylate (**146**) and methyl(4-chloro-1,6-dihydroxy-3-methylxanthone)-8-carboxylate (**147**), were isolated by bioassay-guided separation. All metabolites demonstrated moderate to strong antibacterial activity with MIC values ranging from 3.13 to 50 $\mu\text{g mL}^{-1}$ on six Gram-positive bacteria. In particular, the MICs of certain isolates are at the level of positive control.⁵⁹

Three pyrazin-2(1*H*)-one derivatives, ochramide B (**148**), ochralate A (**149**), as well as aluminiumneospargillins (**150**), were isolated from the marine coral-derived halotolerant *Aspergillus ochraceus* LCJ11-102 (fermentation broth in a nutrient-limited medium containing 10% sodium iodide). The isolated derivatives exerted antimicrobial effects with MIC values of 40.0, 18.9 and 20.1 μM , respectively, against *Enterobacter aerogenes*.⁶⁰ Five polyketides were isolated from the marine-derived fungus *Aspergillus* sp. ZF-79, named asperochrins A (**151**), D (**152**) and F (**153**), (3*R*,4*R*)-4,7-dihydroxymellein (**154**), and asteltoxin (**155**). All the isolates were tested for quorum sensing inhibitory activity (QSI), exhibiting QSI activity against *Chromobacterium violaceum* CV026 with MIC values of 50, 100, 50, 50, and 6.25 μM , respectively.⁶¹ A diphenyl derivative, dichloroasterric acid (**141**) was isolated from the fungus *Aspergillus* sp. derived from the soft coral *Sinularia* sp., the South China Sea. Furthermore, five pathogenic bacterial strains, *S. aureus* (ATCC 25923), *Escherichia coli* (ATCC 35401), *Pseudomonas aeruginosa* (ATCC 9027), *Vibrio parahaemolyticus* (ATCC 19019) and *Vibrio anguillarum* (ATCC 17802), were used to investigate the antibacterial activity of this diphenyl derivative (positive control was ciprofloxacin), displaying selective inhibition against *S. aureus* with the MIC value of 12.5 μM .²¹

In the course of investigation on potent nontoxic antibacterial agents from coral-derived fungi in the South China Sea, two biphenyl derivatives with cytotoxic and antimicrobial activities, sulochrin (**156**) and (–)-bis-dechlorogeodin (**157**) were isolated from a soft coral-derived fungus *Aspergillus* sp. These biphenyls were tested on the basis of chemical ecology for their antimicrobial activities against different pathogenic microorganisms, including the bacteria *E. coli*, *P. aeruginosa* and *S. aureus*, exhibiting strong antibacterial activity against *P. aeruginosa* with MICs of 7.53 and 3.78 μM (ciprofloxacin, MIC = 1.88 μM), respectively.⁶²

Investigation of EtOAc extract of a gorgonian-derived fungus, *Aspergillus versicolor* led to the isolation of two seco-anthraquinones, namely (+)-geodin (**32**) and chlorotrypacidin (**34**). The antibacterial effects of both compounds were tested, showing antibacterial activity against *Vibrio anguillarum*, *Staphylococcus albus* and *S. aureus*, with a standardized MIC value of 25.0 μM .²³ Prenylated *p*-terphenyls, prenylterphenyllins H–J (**37–39**), were isolated from the *Aspergillus candidus* LDJ-5 (a marine-endophytic fungus). The three compounds were active as antimicrobials against *Proteus* species, *P. aeruginosa* and *B. subtilis* with IC₅₀ values varying from 22 to 90 $\mu\text{g mL}^{-1}$.²⁴ The fungal strain *Aspergillus alabamensis* EN-547 was derived from

the *Ceramium japonicum*, one of marine red alga species (fresh inner tissue), leading to the isolation of 3 diketomorpholine derivatives, namely 4-*epi*-seco-shornephine A methyl ester (**158**), 4-*epi*-seco-shornephine A carboxylic acid (**159**) and shornephine A (**160**) together with a highly conjugated ergostane-type steroid, 28-acetoxy-12*b*,15*a*,25-trihydroxyergosta-4,6,8(14),22-tetraen-3-one (**161**). These metabolites were assayed for antimicrobial activities against *E. coli* and *Micrococcus luteus* (two human pathogens) and five marine bacteria (*Vibrio alginolyticus*, *Edwardsiella ictaluri*, *V. anguillarum*, *V. vulnificus* and *V. parahaemolyticus*), showing inhibitions against aquatic bacteria (*Ed. ictaluri* and *V. alginolyticus*) and human pathogens (*E. coli* and *M. luteus*), with MIC values ranging between 16 and 64 $\mu\text{g mL}^{-1}$.⁶³

A hydroxypyrrolidine alkaloid, preussin (**81**), a bis-indolyl benzenoid, petromurin C (**42**) and chrysophanic acid (**53**) anthraquinone, were isolated from the *Aspergillus candidus* KUFA 0062, one of marine sponge-associated fungi. For their antibacterial activity against Gram-negative and Gram-positive reference and other environmental multidrug resistant strains, all metabolites were evaluated. Preussin (**81**) exhibited an inhibitory effect against *E. faecalis* ATCC29212 and *S. aureus* ATCC 29213 as well as both vancomycin-resistant enterococci (VRE) and methicillin-resistant *S. aureus* (MRSA) strains. Both preussin (**81**) and chrysophanic acid (**53**) caused significant reduction of biofilm production in *E. coli* ATCC 25922. Moreover, petromurin C (**42**) and preussin revealed a synergistic effect with oxacillin towards MRSA *S. aureus* 66/1 while preussin (**81**) exhibited a strong synergistic inhibition with the colistin antibiotic against *E. coli* 1410/1.³⁰ From the fungus *Aspergillus* sp. ZA-01, seven prenylxanthone derivatives, aspergixanthenes A (**43**) and I–K (**162–164**), and other analogues, 15-acetyl tajixanthone hydrate (**165**), tajixanthone hydrate (**166**), and 16-chlorotajixanthone (**167**) were obtained. All the isolates were tested for their anti-*Vibrio* activities. Aspergixanthone I (**162**) displayed the strongest anti-*Vibrio* activity, in particular against *V. parahaemolyticus* (MIC = 1.56 μM), *V. anguillarum* (MIC = 1.56 μM), and *V. alginolyticus* (MIC = 3.12 μM), whilst other isolates showed inhibition with IC₅₀, ranging between 1.56 and 25.0 μM .⁶⁴

A tetrahydroxanthone dimer, 5-*epi*-asperdichrome (**168**), was isolated from the *Aspergillus versicolor* HDN1009, a mangrove-derived fungus. This compound is a type of tetrahydroxanthone dimers. This dimer showed promising antibacterial activities against *B. subtilis*, *P. aeruginosa* and *V. parahaemolyticus* with MIC values ranging between 100 μM and 200 μM .³¹ A sterol; ergosta-5,7,22-triene-3*b*-ol (**169**), a norsterol; volemolide (**170**), an indole alkaloid; oxaline (**171**), an indolyl diketopiperazine alkaloid; fumitremorgin B (**172**), a tricyclic triterpene; helvolic acid (**173**), and (*E*)-4-oxonon-2-enoic acid (**174**), were purified from the fermentation broth of a bivalve mollusk, *Sanguinolaria chinensis* associated with *Aspergillus* sp. SCS-KFD66, China. The growth inhibitory activity of these metabolites against four pathogenic bacterial strains (*S. aureus* ATCC 6538, *E. coli* ATCC 25922, *Bacillus subtilis* ATCC 6633 and *Listeria monocytogenes* ATCC 1911), were assessed. Inhibitory effect with MIC values ranging from 2 to 128 $\mu\text{g mL}^{-1}$ was

Fig. 8 Chemical structure of compounds 122–139.

observed in all compounds.⁶⁵ Two biphenyl derivatives, diorcinol J (175) and 4-methoxycarbonyldiorcinol (176), were isolated from the *Aspergillus versicolor* OUCMDZ-2738. These compounds showed selective antibacterial effects against *P. aeruginosa* with a MIC of 17.4 and 13.9 μM , respectively.⁶⁶

Three helvolic acid derivatives, namely 16-*O*-propionyl-16-*O*-deacetylhelvolic acid (177), 6-*O*-propionyl-6-*O*-deacetylhelvolic acid (178) and helvolic acid (173), were isolated from the marine-derived fungus *Aspergillus fumigatus* CUGBMF17018. The antibacterial activities against both MRSA and *S. aureus*

Fig. 9 Chemical structure of compounds 140–159.

were shown by these compounds, with MIC values of between 0.78 and 12.5 $\mu\text{g mL}^{-1}$.⁶⁷ Nine prenylated diphenyl ether compounds, diorcinols C–E (179–181), and J (175), (*R*)-diorcinol B (182), (*S*)-diorcinol B (183), 9-acetyldiorcinol B (184), and

a dihydrobenzofuran derivative (87), were isolated from one of the marine algal-derived endophytic fungi, *Aspergillus tennesseensis* (87). These isolates were examined for antimicrobial effects, exhibiting antimicrobial activities against some plant

and human pathogenic microbes (MIC values varying between 2–64 $\mu\text{g mL}^{-1}$).³⁹

An indole alkaloid, fumigatoside F (**185**) and an indole alkaloid, fumiquinazoline G (**186**), were purified from the fungus *Aspergillus fumigatus* SCSIO 41012 (deep-sea derived). Moreover, all compounds were assayed for antibacterial inhibitory activities. Fumiquinazoline G (**186**) exhibited the most significant activities against *S. aureus* (29 213 and 16 339) with MIC values of 0.78 and 1.56 $\mu\text{g mL}^{-1}$, respectively, and an important inhibitory activity against *A. baumannii* ATCC 19606 was seen with fumigatoside F (**185**), with a 6.25 $\mu\text{g mL}^{-1}$ MIC value.⁶⁸ Chemical investigation of the *Aspergillus sydowii* SW9 (sea water-derived fungus) led to the purification of two quinazolinone alkaloids, 2-(4-hydroxybenzyl)-4-(3-acetyl)quinazolin-one (**187**) and 2-(4-hydroxybenzoyl)-4(3H)-quinazolinone (**188**), and one aromatic bisabolene-type sesquiterpenoid (**189**). These metabolites displayed selective inhibitory effects on the human pathogenic bacteria *S. aureus*, *E. coli*, *S. epidermidis* and *Streptococcus pneumoniae*, with MIC values varying between 2.0 and 16 $\mu\text{g mL}^{-1}$.⁶⁹

An anthraquinone, 2-(dimethoxymethyl)-1-hydroxyanthracene-9,10-dione (**190**), was isolated from the deep sea sediment fungus *Aspergillus versicolor*. It showed strong inhibitory activities against MRSA CGMCC 1.12409 and MRSA ATCC 43300 (MIC values of 7.8 and 3.9 $\mu\text{g mL}^{-1}$, respectively). Molecular docking tests were added to this metabolite to suppress the enzymes AmpC β -lactamase and topoisomerase IV, signaling its utility as an antimicrobial agent.⁷⁰ Three diphenyl ethers, diorcinols K (**191**), D (**192**) and I (**193**), were isolated from the marine fungus *Aspergillus* sp. CUGB-F046, the Bohai Sea (a sediment sample), China. Such metabolites displayed considerable antibacterial activities towards methicillin-resistant *S. aureus* with MIC values of 3.125, 6.25 and 6.25 $\mu\text{g mL}^{-1}$, respectively.⁷¹ Circumdatin F (**194**), a benzodiazepine alkaloid was purified from the deep sea fungus *Aspergillus westerdijikiae* SCSIO 05233 that was isolated from a sediment sample collected at the depth of 4593 m from the South China Sea. This alkaloid was examined for antifouling activity, displaying remarkable antifouling activity with EC_{50} value of 8.81 $\mu\text{g mL}^{-1}$.⁷² A study of the fungal strain *A. wentii* SD-310 described the isolation of five 20-nor-isopimarane diterpenoids, namely aspewentins A (**195**), D (**196**), F–H (**197–199**). All the isolates were evaluated for their antimicrobial effects against seven aquatic pathogens and two human pathogenic bacteria, showing inhibitory activity against various aquatic pathogens *Micrococcus luteus*, *Edwardsiella tarda*, *Pseudomonas aeruginosa*, *Vibrio parahaemolyticus* and *V. harveyi*, each with MIC values of 4.0 $\mu\text{g mL}^{-1}$.⁷³

An antibacterial anthraquinone, 2-(dimethoxymethyl)-1-hydroxyanthracene-9,10-dione (**200**), was separated from a marine deep sea-derived *A. versicolor*, recovered from sediments collected at a depth of 2869 m in the West Pacific Ocean. The anthraquinone displayed strong antibacterial activities against MRSA CGMCC 1.12409 and MRSA ATCC 43300 (MIC values of 7.8 and 3.9 $\mu\text{g mL}^{-1}$, respectively). Molecular docking studies of the anthraquinone with AmpC β -lactamase and topoisomerase IV showed least binding energy.⁷⁴

A highly conjugated steroid, (22E)-ergosta-4,6,8(14),22,24(28)-pentaen-3-one (**201**), together with two steroid derivatives, (4S,17R)-4-hydroxy-17-methylincisterol (**202**) and chaxine C (**203**),

in addition to five butyrolactone derivatives, 2-O-methylbutyrolactone I (**204**) and II (**205**), demethoxycarbonylbutyrolactone II (**206**), butyrolactones I (**207**) and III (**208**), were isolated from the marine-derived fungus *Aspergillus* sp. XS-20090B15 recovered from the fresh gorgonian *Muricella abnormalis*, The South China Sea (the Xisha Islands coral reef). The 2-O-methylbutyrolactone I (**204**) and II (**205**) butyrolactone derivatives demonstrated significant antibacterial activities against *S. Aureus* with a MIC value of 1.56 μM . On the other hand, the steroid derivatives, (22E)-Ergosta-4,6,8(14),22,24(28)-pentaen-3-one (**201**), (4S,17R)-4-hydroxy-17-methylincisterol (**202**), chaxine C (**203**) in addition to the butyrolactone derivatives, 2-O-methylbutyrolactone II (**205**), demethoxycarbonylbutyrolactone II (**206**), butyrolactone I (**207**) and III (**208**) displayed potent antifouling activities against *Balanus amphitrite* with EC_{50} values ranging between 0.63 and 18.4 $\mu\text{g mL}^{-1}$.⁷⁵ Di-(2-ethyl-hexyl) phthalate (DEHP; **115**) compound from fungus *Aspergillus awamori* also exhibited activity against Gram positive bacteria *Sarcina lutea* with inhibition diameter zone of 23 mm.⁴⁹ All antibacterial marine-derived *Aspergillus* metabolites are depicted in Fig. 2, 3, 5 and 7–12.

Anti-inflammatory

An ochratoxin derivative named ochratoxin A₁ (**209**) was obtained from the *Aspergillus ochraceopetaliformis*, a sponge-derived fungus. Ochratoxin A₁ (**209**) exhibited anti-inflammatory activity against IL-6 of the LPS-induced THP-1 cells and against TNF- α expression with inhibitory rates of 67.7% and 74.4 at concentration of 10 μM , respectively.⁷⁶ Two Diels–Alder additive steroids, ergosterdiacids A (**210**) and B (**211**), were obtained from the *Aspergillus* sp. DM29 (mangrove-derived fungus strain). These steroids displayed strong *in vitro* anti-inflammatory effects *via* the NO production suppression at 4.5 and 3.6 μM , respectively.⁷⁷ Aromatic butenolides, asperimides C (**212**) and D (**213**) were isolated from of a tropical endophytic fungus *Aspergillus terreus* SC1550 (solid cultures). The inhibitory effects of these butenolides on nitric oxide (NO) production were studied in lipopolysaccharide (LPS)-mediated RAW 264.7 cells, exhibiting a powerful anti-inflammatory effect with IC_{50} values of 0.78 ± 0.06 and 1.26 ± 0.11 μM .⁷⁸ Deoxy-7,14-didehydrodydonol (**214**), a sesquiterpene derivative was obtained from *Aspergillus versicolor* SYSU-SKS025, a mangrove endophytic fungus. This metabolite exerted inhibition of NO production in RAW 264.7 macrophages with IC_{50} value of 12.5 μM .⁷⁹

A fungal metabolite, 6,8,1'-tri-O-methylaverantin, an anthraquinone (**215**) was isolated from the *Aspergillus* sp. SF-6796, a marine-derived fungal strain. This anthraquinone induces heme oxygenase (HO)-1 protein up-regulation, which is present in microglial BV2 cells. HO-1 protein induction was mediated by the activation of Nrf2 (nuclear transcription factor erythroid-2 associated factor 2), and additionally was regulated by phosphatidylinositol 3-kinase/protein kinase B and the p38 mitogen-activated protein kinase signaling pathways. In addition, 6,8,1'-tri-O-methylaverantin (**215**) caused overproduction suppression of prostaglandin E2 and NO (pro-inflammatory mediators), such as, with IC_{50} values of 2.59 ± 0.39 and 5.62

Fig. 10 Chemical structure of compounds 160–173.

± 0.18 mM, respectively, inducible cyclooxygenase-2 and nitric oxide synthase, in lipopolysaccharide (LPS)-stimulated BV2 microglial cells. The anti-neuroinflammatory effects were mediated *via* the down-regulation of the nuclear factor kappa B (NFKB) mechanistic pathway, suppressing translocation into the nucleus of p65/p50 heterodimer, the degradation and phosphorylation of inhibitor kappa B- α and p65 subunit DNA-

binding activity. A selective HO-1 inhibitor has partly repressed the anti-neuroinflammatory activity of 6,8,1'-tri-*O*-methylaverantin (215), indicating that its anti-neuroinflammatory effect is relatively mediated by induction of HO-1. HO-1 protein expression in primary microglial cells is also up-regulated by 6,8,1'-tri-*O*-methylaverantin (215), which

may be associated with anti-neuroinflammatory effects found in LPS-stimulated primary microglial cells.⁸⁰

Butyrolactone-I (ZB5-1; **216**) from the *Aspergillus terreus* (coral-derived fungus) was explored for its anti-neuroinflammatory activity on lipopolysaccharide (LPS)-induced BV-2 microglia cells. ZB5-1 (**216**) in tested concentrations significantly reduced the production of NO, and interleukin-1 beta (IL-1 β). The dose-dependent expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) was also down-regulated by ZB5-1 (**216**). Moreover, the effect of ZB5-1 (**216**) on the signaling pathway of nuclear factor- κ B (NF- κ B) that was studied through evaluation of the expression of phosphorylation of inhibitor of NF- κ B and (I κ B) NF- κ B p65, and the nuclear translocation of NF- κ B p65, respectively. Moreover, molecular docking study proposed that ZB5-1 (**216**) bound at the NF- κ B active sites, preventing its translocation to the nucleus.⁸¹ Three derivatives of ochratoxin, called ochratoxin A1 (**209**), ochratoxin B (**68**) and ochratoxin B methyl ester (**217**) were isolated from the *Aspergillus ochraceo-petaliformis*, a sponge-derived fungus. These ochratoxins exhibited anti-inflammatory activity against expression of both TNF- α and IL-6 of the LPS-induced THP-1 cells with inhibitory rates of 67.7%, 74.4 (ochratoxin A1; **209**), 72.8%, 91.6 (ochratoxin B; **68**) and 72.9%, 89.7% (ochratoxin B methyl ester; **217**) at a uniform concentration of 10 μ M, respectively.⁸²

Aspersecosteroids A (**218**) and B (**219**), 11(9 $\rightarrow$ 10)-abeo-5,10-secosteroids together with an ergosteroid named asperflosterol (**220**), were purified from the sponge-derived fungus *Aspergillus flocculosus* 16D-1. These steroids displayed inhibitory activities on key pro-inflammatory cytokine output in THP-1 cells. Wagner-Meerwein rearrangement, oxidative cleavage (biogenetic pathway) and sequential acetalization as key steps is suggested for the two secosteroids.⁸³ A prenylated tryptophan derivative, luteoride E (**221**), a butenolide derivative, versicolactone G (**222**), a linear aliphatic alcohol, (3*E*,7*E*)-4,8-dimethyl-undecane-3,7-diene-1,11-diol (**223**), together with an alkaloid, methyl 3,4,5-trimethoxy-2-(2-(nicotinamido)benzamido)benzoate (**224**), a steroid, 14 α -hydroxyergosta-4,7,22-triene-3,6-dione (**225**), teritrem A (**226**), and lovastatin (**227**), were isolated from *Aspergillus terreus*, a coral-associated fungus. These isolates were evaluated for their anti-inflammatory activity against NO production, exhibiting potent inhibition with IC₅₀ values ranging between 5.48 and 29.34 μ M.⁸⁴

Three meroterpenoids, aspermeroterpenes A–C (**228–230**), were isolated from *Aspergillus terreus* GZU-31-1, a marine-derived fungus. These compounds displayed significant inhibitory effects against lipopolysaccharide (LPS)-induced nitric oxide (NO) production in RAW 264.7 cells with IC₅₀ values ranging from 13.4 to 17.8 μ M compared to positive controls (indomethacin IC₅₀ = 24.0 μ M).⁸⁵ Three pyrrolidine alkaloids, preussin I (**231**), (11*R*)/(11*S*)-preussins J–K (**232–233**), were isolated from *Aspergillus flocculosus* 16D-1, a sponge-derived fungus. In lipopolysaccharide-induced THP-1 cells with IC₅₀ values of 0.11, 0.19 and 2.3 μ M, respectively, these compounds displayed substantial inhibition against IL-6 production.⁸⁶ Asperseramide B–C (**234–235**) and F–G (**236–237**), four linearly fused prenylated indole alkaloids, were isolated from *Aspergillus*

versicolor, a marine-derived fungus. The anti-inflammatory activities of these alkaloids were all tested, exhibiting potential iNOS inhibitory activities and inhibited the release of NO in LPS-induced RAW 264.7 with IC₅₀ values, ranged between 5.39 and 9.95 μ M (iNOS) and between 17.24 $\pm$ 1.32 and 25.09 $\pm$ 2.21 μ M (NO release).⁸⁷ All anti-inflammatory marine-derived *Aspergillus* metabolites are depicted in Fig. 3, 7–9.

Antidiabetic activity

Two new lumazine-containing peptides, terrelumamides A (**238**) and B (**239**), were obtained from *Aspergillus terreus* FA009 fungal strain cultivated from marine sediments, Jeju Island, Korea. These peptides improved insulin sensitivity that was tested in an adipogenesis model using stem cells of human bone marrow mesenchymal. Moreover, the peptides showed fluorescence changes from binding to DNA, indicating their possible applications for DNA sequence recognition.⁸⁸ Flaviposolides A–C (**240–242**), three butenolide derivatives, in addition to 7 compounds; 5-[(3,4-dihydro-2,2-dimethyl-2*H*-1-benzopyran-6-yl)methyl]-3-hydroxy-4-(4-hydroxyphenyl)-2(5*H*)furanone (**243**), aspernolide A (**244**), emodin (**245**), geodin hydrate (**143**), methylchloroasterrate (**246**), monomethylsoic acid (**139**), epicoccolide B (**30**), were isolated from the *Aspergillus flavipes* HN4-13 fungus grown from a sediment sample in the coastal region of Lianyungang, China. The noncompetitive α -glucosidase inhibitors (K_i /IC₅₀ values = 0.43/34, 2.1/37, 0.79/19, and 2.8/90 μ M, respectively) were 5-[(3,4-dihydro-2,2-dimethyl-2*H*-1-benzopyran-6-yl)methyl]-3-hydroxy-4-(4-hydroxyphenyl)-2(5*H*)furanone (**243**), aspernolide A (**244**), emodin (**245**) and methylchloroasterrate (**246**). Mixed α -glucosidase inhibitors with K_i /IC₅₀ values of (2.5, 19)/44, (3.4, 14)/57, (9.2, 4.7)/95, (6.3, 5.5)/55, (1.4, 0.60)/9.9, and (2.5, 7.2)/33 μ M, respectively (IC₅₀ 79 μ M for acarbose and 101 μ M for 1-deoxynojirimycin) are the compounds flaviposolides A–C (**240–242**), geodin hydrate (**143**), monomethylsoic acid (**139**), and epicoccolide B (**30**).⁸⁹

A bisabolone sesquiterpene, deoxy-7,14-didehydroxydonol (**214**) was also evaluated for its α -glucosidase inhibitory activity. This sesquiterpene displayed strong inhibitory activity against α -glucosidase with IC₅₀ value of 7.5 μ M.⁷⁹ Diketopiperazine dimer alkaloids, SF5280-415 (**247**) and SF5280-451 (**248**) were isolated from the marine-derived fungus *Aspergillus* sp. SF-5280 (EtOAc extract) by various chromatographic methods. These alkaloids showed inhibitory effects towards PTP1B activity (for diabetes and obesity) with IC₅₀ = 12.9 $\pm$ 0.7 μ M.⁹⁰ ($\pm$)-tylopilus D (**249**), a racemate of a diphenolic derivative, a phenalenone, funalenone (**250**), four polyketide naphthopyrones, rubrofusarin B (**109**), TMC-256A1 (**251**), aurasperone F (**252**), and fonsecin (**253**), together with malformin A1 (**254**), were isolated from *Aspergillus* sp. SF-5929, a marine-derived fungal strain. These isolates were evaluated for their inhibitory effects against protein tyrosine phosphatase 1B (PTP1B) activity, resulting in inhibition of PTP1B activity with IC₅₀ values ranging between 3.3 and 8.1 μ M.⁹¹

Butenolide derivatives ($\pm$)-asperteretal D (**255**), asperteretal E (**256**), flaviposolides B–C (**241–242**), butyrolactones I (**207**), II

Fig. 11 Chemical structure of compounds 174–193.

(257), and 5-[(3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-6-yl)-methyl]-3-hydroxy-4-(4-hydroxyphenyl)-2(5H)-furanone (258), were obtained from the marine-derived sponge *Phakellia fusca* fungus *Aspergillus terreus*. Those butenolides exhibited

significant inhibitory activities against α -glucosidase with IC_{50} values of 8.65 ± 0.4 – 9.98 ± 0.8 , 13.36 ± 1.1 , 10.3 ± 0.6 , 7.63 ± 0.4 , 14.18 ± 1.03 , and $11.65 \pm 0.7 \mu M$, respectively (acarbose, positive control with an IC_{50} value of $320 \mu M$).⁹² A butenolide derivative,

Fig. 12 Chemical structure of compounds 194–213.

versicolactone G (222), was isolated from a coral-associated *Aspergillus terreus* fungus. An inhibitory potential with an IC_{50} value of $104.8 \pm 9.5 \mu M$ (positive control acarbose $IC_{50} = 154.7 \pm$

$8.1 \mu M$) was tested for alpha-glucosidase inhibitory activity of this isolate.⁸⁴ A meroterpenoid identified as (*R,E*)-3-(2,2-dimethylchroman-6-yl)-4-hydroxy-5-((2-(2-hydroxypropan-2-yl)-2,3-

Fig. 13 Chemical structure of compounds 214–231.

dihydrobenzofuran-5-yl)methylene)furan-2(5H)-one (259), a halogenated furanone, rubrolide S (7) and a butenolide derivative, butyrolactone I (207), were isolated from *Aspergillus terreus*

OUCMDZ-2739 upon chemical-epigenetic culture with 10 mM trichostatin A (TSA). These compounds demonstrated greater inhibition of alpha-glucosidase than acarbose and 1-

Fig. 14 Chemical structure of compounds 232–247.

deoxynojirimycin (positive controls) with IC_{50} values of 24.8, 1.2, 61.6, 555.1 and 191.7 μM , respectively. Furthermore, the enzyme kinetics analysis suggested that rubrolide S (7) was an anticompetitive inhibitor (1.42 μM K_i value).¹³ Versicolactone G (222) was

also tested for alpha-glucosidase inhibitory activity. This isolate demonstrated high inhibitory potency (IC_{50} value = 104.8 ± 9.5 μM), whilst (IC_{50} of acarbose positive control = 154.7 ± 8.1 μM).⁹³ Two phenolic bisabolane sesquiterpenoids (*E*)-3-(3-hydroxy-4-(6-

Fig. 15 Chemical structure of compounds 248–264.

methylhept-2-en-2-yl)benzyl)-2,5-dimethylphenol (260) and peniciaculin B (261) and derivatives containing phenolic bisabolane sesquiterpenoid and diphenyl ether units namely, peniciaculin A (262) and expansol D (263), were isolated from the *Kandelia*

obovata-endophytic fungus *Aspergillus flavus* QQSG-3. All metabolites were tested for their alpha-glucosidase inhibitory action, showing potent inhibitory effects with IC_{50} values of 4.5, 3.1, 1.5, and 2.3 μ M, respectively.⁹⁴

The biphenyl derivatives diorcinol E (**181**), diorcinol J (**175**) and diorcinol (**18**), were isolated from the marine *Aspergillus versicolor* OUCMDZ-2738 fungus in chemical-epigenetic 10 μ M vorinostat cultures (SAHA). These biphenyls displayed α -glucosidase inhibitory activity with IC_{50} values of 117.3, 275.3 and 117.3 μ M, respectively. Both diorcinols E (**181**) and J (**175**) displayed better α -glucosidase inhibitory effect than the positive control acarbose (IC_{50} = 255.3 μ M).⁶⁶ All antidiabetic marine-derived *Aspergillus* metabolites are depicted in Fig. 2, 4, 7–9 and 11–15.

Antiviral activity

A number of phenolic compounds including two anthraquinones, aspergilols H–I (**264**–**265**), in addition to an anthraquinone compound, coccoquinone A (**266**), were identified from the fungus *A. versicolor* SCSIO 41502 (=DFFSCS010), a deep-sea-derived strain that had been recovered from the South China Sea (marine sediment sample). Compounds aspergilol H (**264**), I (**265**) and coccoquinone A (**266**) displayed strong antiviral activity against herpes simplex virus types 1 (HSV-1) with EC_{50} values of 4.68, 6.25, and 3.12 μ M, respectively.⁹⁵

Asteltoxins E (**267**) and F (**268**) polyketides were obtained from *Aspergillus* sp. SCSIO XWS02F40, a marine sponge-derived fungus. Asteltoxin E (**267**) and F (**268**) demonstrated potent antiviral activity against influenza virus A subtype H3N2 (A/H3N2) with the very low IC_{50} values of 6.2 ± 0.08 and 8.9 ± 0.3 μ M, respectively. Furthermore, asteltoxin E also revealed inhibitory activity against influenza virus A subtype H1N1 (A/H1N1) with an IC_{50} value of 3.5 ± 1.3 μ M.⁹⁶ A meroterpenoid, named austalide U (**269**) was isolated from the sponge-derived *Aspergillus aureolatus* HDN14-107 fungus. Austalide U (**269**) revealed antiviral activity against A/H1N1, with IC_{50} values of 90 μ M.⁹⁷ Two prenylated benzaldehyde derivatives, namely isodihydroauroglauin (**15**) and flavoglauin (**16**) were isolated from the fungus *Aspergillus ruber* collected from the Xisha Islands. The two benzaldehyde derivatives showed significant antiviral activity against HSV-1 virus.⁹⁸ Three xanthenes, namely methyl-(2-chloro-1,6-dihydroxy-3-methylxanthone)-8-carboxylate (**270**), methyl-(4-chloro-1,6-dihydroxy-3-methylxanthone)-8-carboxylate (**271**) and methyl-(1,6-dihydroxy-3-methylxanthone)-8-carboxylate (**272**), were isolated from *Aspergillus iizukae* (coastal saline soil-derived). These xanthenes were evaluated for their antiviral activity, and methyl-(4-chloro-1,6-dihydroxy-3-methylxanthone)-8-carboxylate (**271**) exhibited definitely strong activity towards herpes simplex virus types 1 (HSV-1), 2 (HSV-2) and A/H1N1 with IC_{50} values of 21.4, 76.7 and 44.6 μ M, respectively, which suggested that it was worth to further study this xanthone as a potential lead compound.⁹⁹

Two xanthenes, 2-hydroxy-1-(hydroxymethyl)-8-methoxy-3-methyl-9H-xanthen-9-one (**273**) and 2-hydroxy-1-(hydroxymethyl)-7,8-dimethoxy-3-methyl-9H-xanthen-9-one (**274**), two anthraquinones, quetin (**133**) and emodic acid (**275**) and a dibenzofurane, 3,7-dihydroxy-1,9-dimethyldibenzofuran (**276**), were isolated from the fungus *Aspergillus sydowii* SCSIO 41,301 collected from the sponge *Phakellia fusca*. All metabolites were tested for their antiviral activity. They displayed prominent selective inhibitory

activities against two subtypes of influenza A virus, including A/FM-1/1/47 (H1N1) and A/Puerto Rico/8/34 (H1N1), with IC_{50} values varying between 2.17 ± 1.39 and 4.70 ± 1.11 μ M. The dibenzofurane compound also displayed obvious selective inhibitory activities against A/Aichi/2/68 (H3N2) with IC_{50} value of 1.24 ± 0.14 μ M.¹⁰⁰ A meroterpenoid, apterterpene N (**277**), was isolated and identified from *Aspergillus terreus* EN-539, one of marine algal-derived endophytic fungi. This meroterpenoid showed inhibitory activity against influenza neuraminidase (IC_{50} = 18.0 nM).⁵⁴ All antiviral marine-derived *Aspergillus* metabolites are depicted in Fig. 1, 8, 15 and 16.

Anti-oxidant activity

A number of phenolic compounds including compounds, 6-methylbenzene-1,2,4-triol (**278**), violaceol-II (**279**), cordylol C (**64**) and sydowiols B (**280**), E (**281**) and D (**282**) were separated from the deep-sea-derived fungus *A. versicolor* SCSIO 41502 (=DFFSCS010) that had been recovered from a marine sediment sample, the South China Sea. With IC_{50} values of 18.92–52.27 μ M against DPPH radicals, the phenolic isolates exhibited antioxidant activity greater than L-ascorbic acid.⁹⁵ Application of the OSMAC approach through adding bromide containing salts (CaBr₂ and NaBr) during fermentation of *Aspergillus niger* (marine-mudflat-derived fungus) resulted in the development of a brominated naphthopyranone, named 6,9-dibromoflavasperone and three compounds; TMC-256A1 (**251**), fonsecin (**253**) and aurasperone B (**283**). The marine mudflat (from which the fungus *Aspergillus niger*, was cultivated) had been collected at Suncheon Bay, Jeonnam Province, Korea. All the isolated compounds exhibited potent radical scavenging activity against DPPH (2,2-diphenyl-1-picrylhydrazyl), with IC_{50} values of 21, 25, 0.3, 0.02, and 0.01 μ M, respectively. Compounds TMC-256A1 (**251**), fonsecin (**253**) and aurasperone B (**283**) were more potent than ascorbic acid (the positive control, IC_{50} = 20.0 μ M).¹⁰¹

Seven phenolic compounds were purified from the marine-derived fungus *Aspergillus versicolor*; cordylol C (**64**), methylgerfelin (**284**), violaceol II (**279**), 10-O-methylaverantin (**285**), lecanoric acid (**286**), 1-methylpyrogallol (**287**), and fumatic acid (**288**). The fungus *A. versicolor* (A-21-2-7) was cultured from the deep-sea sediments, Southern China Sea. The isolates were investigated for their TEAC (trolox equivalent antioxidant capacity). Cordylol C (**64**), lecanoric acid, 1-methylpyrogallol (**287**), and fumatic acid (**288**) were proved to possess stronger free-radical scavenging effects, about five folds than trolox (positive control). Furthermore, the Nrf2-regulated gene expression, as found in the Nrf2-dependent luciferase reporter gene assay, was potentially activated by cordylol C (**64**), methylgerfelin (**284**), violaceol II (**279**), 10-O-methylaverantin (**285**) and lecanoric acid (**286**).¹⁰² 2-Pyrone derivatives, sydowiones A–B (**289**–**290**), were isolated from *Aspergillus sydowii* SCSIO 00305, a marine-derived fungus. They showed antioxidant activity against 2,2-diphenyl-picrylhydrazyl (DPPH) radicals with IC_{50} values of 46.0 and 46.6 μ M, respectively.¹⁰³ The cultured fungus *Aspergillus europaeus* WZXY-SX-4-1 (EtOAc extract) isolated from the marine-derived sponge *Xestospongia testudinaria*, was

Fig. 16 Chemical structure of compounds 265–282.

evaluated, displaying radical scavenging activity (RSA). Therefore, polyketide derivatives, namely eurobenzophenone C (291), 3-de-O-methylsulochrin (105) and 14-de-O-methyl-5-methoxysulochrin (292), were isolated from the mentioned

bioactive fraction. These polyketides showed strong RSA against DPPH with IC_{50} values of 1.7 ± 0.2 , 2.3 ± 0.1 and $5.4 \pm 0.1 \mu\text{g mL}^{-1}$, respectively.⁴³

Fig. 17 Chemical structure of compounds 283–298.

Butenolide derivatives, asperterretal E (256), butyrolactone III (208) and aspernolide A (244), B (293), were isolated from the fungus *Aspergillus terreus*. SCSIO FZQ028, South China Sea deep-sea sediment. All the derivatives were evaluated for their

antioxidative activities against DPPH, showing potent activities against DPPH (IC_{50} ranging between 5.89 and $10.07 \mu\text{g mL}^{-1}$).¹⁰⁴ Azacoccones C (294) and E (295), aza-epicoccone derivatives, were isolated from the marine-derived *Aspergillus flavipes*

Fig. 18 Chemical structure of compounds 299–316.

culture. These derivatives demonstrated substantial free radical scavenging effects that were greater than positive control trolox (IC_{50} values of 4.0, 2.4 and $4.55 \mu\text{g mL}^{-1}$ respectively).¹⁰⁵ EtOAc

extract of *Aspergillus versicolor* fungus derived from deep-sea sediments leading to the isolation of four anthraquinones, UCT1072M1 (296), averantin (297), averythrin (298) and

Fig. 19 Chemical structure of compounds 317–332.

nidurufin (299). These isolates potentially triggered the expression of Nrf2 (the nuclear factor E2-related factor 2), a transcription factor that consistent with oxidative stress by

binding to ARE (the antioxidant response element) in the genes promoter coding for antioxidant proteins and enzymes for glutathione synthesis with 1.49 ± 0.28 , 1.58 ± 0.11 , 1.46 ± 0.08 ,

and 1.41 ± 0.05 folds, respectively compared to control.¹⁰⁶ All anti-oxidant marine-derived *Aspergillus* metabolites are depicted in Fig. 3, 12, 14, 15 and 16–18.

Antifungal activity

DEHP (115) also exhibited activity against *Candida albicans* fungus with inhibition diameter zone of 20 mm.⁴⁹ Reporting the bioassay-guided purification of bioactive fatty acid derivatives, a butenolide, namely sinulolide I (300) together with three common metabolites, (9Z,12Z)-N-(2-hydroxyethyl) octadeca-9,12-dienamide (301), dodecanoic acid (302) and decanoic acid (303), were isolated from *Aspergillus terreus* SCSIO 41202 from the deep-sea sediment. These compounds displayed significant antifungal activity against *Penicillium italicum* (citrus postharvest pathogen) with MIC values around 0.125, 0.062, 0.031 and 0.062 mg mL⁻¹, respectively.¹⁰⁷ A 20-nor-isopimarane diterpenoid epimer, aspewentin M (304), was isolated from *Aspergillus wentii* SD-310 fungus from the deep sea sediment. This compound was tested for plant-pathogenic fungi, showing potent activity against *Fusarium graminearum*.¹⁰⁸ An indole alkaloid, namely fumigatoside E (305) was purified from deep-sea fungal *Aspergillus fumigatus* SCSIO 41012. In addition, it

was evaluated for its antifungal inhibitory activities, showing potent antifungal effect towards *Fusarium oxysporum* f. sp. *momordicae*, with MIC of 1.56 $\mu\text{g mL}^{-1}$.⁶⁸

On the course of anti-saprolegniasis metabolites from numerous cultured broths of various deep-sea fungal strains, three diphenyl ethers, diorcinol (18), violaceol-I (306) and violaceol-II (279), were isolated from the deep-sea derived fungus *Aspergillus* sp. YK-76 originated from an *Osedax* sp. annelid. These compounds showed anti-*S. parasitica* activity, suggesting that diorcinol (18) and violaceol analogs could have their potential to be used as saprolegniasis preventing candidates.¹⁰⁹ Chitinase enzyme (307) was produced from unconventional sources, the marine-derived fungus *Aspergillus griseoaurantiacus* KX010988 by solid state fermentation of potato shells. Chitinase enzyme (307) showed good antifungal activity against *F. solani* with inhibition zone diameter = 23 ± 1.20 .⁵² An indoloditerpene, (3R,9S,12R,13S,17S,18S)-2-carbonyl-3-hydroxylemeniveol (126) was isolated from a marine-derived fungus *Aspergillus versicolor* ZZ761. This indoloditerpene showed antimicrobial activities with MIC value of 22.8 μM against *Candida albicans*.¹⁷ Prenylated *p*-terphenyls, prenylterphenyllins H–J (37–39), were isolated from the marine-derived endophytic fungus *Aspergillus candidus* LDJ-5. The

Fig. 20 (A) Natural products isolated from marine-derived genus *Aspergillus* according to the year of publication, (B) bioactivities of natural products derived from marine-derived genus *Aspergillus*, (C) secondary metabolites classes derived from marine-derived genus *Aspergillus*.

three compounds are active as antimicrobials against *Monilia albicans* with IC_{50} values varying from 22 to $90 \mu\text{g mL}^{-1}$.²⁴ A study of the fungal strain described the isolation of a rare class of fungal metabolites, 20-nor-isopimarane diterpenoids, upon implementation of different fungal cultivation conditions. Aspewentins D (196), H (199), were obtained from the *A. wentii* SD-310 EtOAc extract. These compounds were tested against four plant pathogenic fungi for their antifungal activity and showed activity against *F. graminearum*, with MIC values of 2.0 and $4.0 \mu\text{g mL}^{-1}$, which are smaller than that of the positive control amphotericin B (MIC = $8.0 \mu\text{g mL}^{-1}$), respectively.⁷³ All antifungal marine-derived *Aspergillus* metabolites are depicted in Fig. 1, 2, 7, 8, 12, 16 and 18.

Neuroprotective activity

An auroglaucon-derived compound, niveoglaucin A (308) and a prenylated benzaldehyde derivative, flavoglaucin (16), were isolated from the extract of *Aspergillus niveoglaucus* (a marine sediment-derived strain). The neuroprotective activity in 6-OHDA-induced Parkinson's disease cell model was shown for both compounds, resulting in increased viability of 6-OHDA-treated cells by 20–25%.¹¹⁰ The neuroprotective activities of diketopiperazine mactanamide (51) from *Aspergillus flocculosus* and prenylated *p*-terphenyls, candidusin A (309) and 4''-dehydrocandidusin A (310) from *Aspergillus* sp. KMM 4676, were

evaluated in the paraquat (PQ)-induced Parkinson's disease (PD) and 6-hydroxydopamine (6-OHDA)- cell models. These metabolites protected Neuro2a cells against the 6-OHDA damaging influence to varying degrees, which might be realized *via* ROS scavenging pathway. Dehydroxylation at C-4'' and C-3'' remarkably increased neuroprotective activity and ROS scavenging of candidusin-related *p*-terphenyls in both the PQ-induced PD and 6-OHDA-models.¹¹¹ Four echinulin-related indole-diketopiperazine alkaloids, namely (–)-Cryptoechinuline B (311), neocheinulin (312), and neocheinulins B–C (313–314), were isolated from the fungus *Aspergillus niveoglaucus* (Vietnamese sediment-derived). (+)-Cryptoechinuline B (311) displayed neuroprotective activity in rotenone, paraquat- and 6-OHDA-induced *in vitro* Parkinson's disease models. (–)-Cryptoechinuline B (311) and neocheinulin C (314) have shown substantial neuronal cell defense against paraquat-induced damage. In the 6-OHDA-induced model, neocheinulin (312) showed activity and neocheinulin B (313) exhibited cytoprotective activity in a rotenone-induced model.¹¹² All neuroprotective marine-derived *Aspergillus* metabolites are depicted in Fig. 1, 3 and 18.

Antimycobacterial activity

Ergosterdiacids A (210) and B (211) were obtained from *Aspergillus* sp. DM29, one of mangrove-derived fungi (see Anti-

Fig. 21 Distribution of metabolites (divided in chemical classes) isolated from marine-derived genus *Aspergillus* in (A) anticancer activity, (B) antibacterial activity, (C) anti-inflammatory activity and (D) antidiabetic activity.

Fig. 22 Distribution of metabolites (divided in chemical classes) isolated from marine-derived genus *Aspergillus* in (A) antiviral activity, (B) antioxidant activity, (C) neuroprotective activity and (D) antifungal activity.

inflammatory section). In the bioactivity assays, these steroids exhibited potential *in vitro* inhibition effect against MptpB (*Mycobacterium tuberculosis* protein tyrosine phosphatase B) with an IC_{50} value of 15.1 and 30.1 μM , respectively. The experimentations concerning inhibitory kinetic indicated that both steroids acted *via* a noncompetitive inhibition mechanistic pathway.⁷⁷ Butyrolactone I (207), a polyketide was obtained from *Aspergillus terreus* SCSIO 41008 (a marine sponge-derived fungus). It showed significant inhibitory effects against MptpB, with the IC_{50} of $5.11 \pm 0.53 \mu mol L^{-1}$. This butyrolactone acted *via* a noncompetitive inhibition based on kinetic analysis.¹¹³ Prenylterphenyllin I (38), a prenylated *p*-terphenyl was isolated from the marine-derived endophytic fungus, *Aspergillus candidus* LDJ-5. This compounds was found to be antimicrobial against *Mycobacterium phlei* with IC_{50} value of 45 $\mu g mL^{-1}$.²⁴ All antimycobacterial marine-derived *Aspergillus* metabolites are depicted in Fig. 2 and 12.

Miscellaneous activities

A number of phenolic compounds including 4-carbglyceryl-3,3'-dihydroxy-5,5'-dimethyldiphenyl ether (315), sydowiols B (280), E (281) and D (282), and 2,4-dihydroxy-6-(4*S*-hydroxy-2-oxopentyl)-3-methylbenzaldehyde (316), were separated from the *A. versicolor* SCSIO 41502 (=DFSCS010), one of deep-sea-derived fungal strains that had been recovered from a marine sediment sample, the South China Sea. These phenolic compounds exhibited significant antifouling activity towards

a larval settlement *Bugula neritina* with EC_{50} values of 1.28, 2.61, 5.48, 1.59, and 3.40 $\mu g mL^{-1}$, respectively.⁹⁵

Epigenetic modification of the marine-derived fungus *Aspergillus* sp. SCSIO3 obtained from a deep marine sediment sample collected in the South China Sea, elicited the isolation of two compounds; diorcinal (317) and cordylol (318). The bio-membrane defensive role of erythrocytes has been shown by these compounds. Algicidal action against *Chattonella marina*, an alga causing large-scale fish kills, was also seen with diorcinal (317).¹¹⁴

Versiquinazolines A (319), B (320) and G (321), fumiquinazoline-type alkaloids, were separated from the gorgonian (*Pseudopterogorgia* sp.)-derived *Aspergillus versicolor* LZD-14-1 fungus, the South China Sea. These metabolites exhibited inhibitory activities towards thioredoxin reductase, with IC_{50} values of 20, 12 and 13 μM , respectively.¹¹⁵ An artifact drimane derivative, 11,12-*O*-isopropylidene-6-*epi*-albrassitriol ester of (*E,E*)-6,7-dihydroxy-2,4-octadienoic acid (322) was isolated from *Aspergillus ustus* KMM 4664, a marine-derived fungus. This drimane exhibited significant inhibition effect of spermatozoa, fertilizing egg-cells of the *Strongylocentrotus intermedius* (sea urchin) with IC_{50} value of 21 μM .¹¹⁶

A γ -lactone, aspergilactone A (323) and pericoterpenoid A (324), a naphthalene carboxylic acid derivative, were purified from the sponge-associated fungus *Aspergillus* sp. LS45. These metabolites were investigated in a variety of bioassays, and both metabolites showed strong inhibitory activity against the

Fig. 23 Distribution of metabolites (divided in chemical classes) isolated from marine-derived genus *Aspergillus* in (A) antimycobacterial activity, (B) other activities.

Arabidopsis thaliana Columbia-0 lateral root growth at a concentration of 100 μM .¹¹⁷ Depsidone derivatives, namely nornidulin (325), nidulin (326) and aspergillusidones A (327) and F (328), were isolated from the marine-derived fungus *Aspergillus unguis*. Nornidulin (325), nidulin (326) and aspergillusidones F (328) displayed potent larvicidal activity against brine shrimp with IC_{50} values of 12.8, 4.5 and 12.8 μM , respectively, indicating that plasma mutagenesis and chemical induction could be utilized as tools to the chemodiversity of fungi and to purify useful natural products. In addition, aspergillusidone A (327) inhibited acetylcholinesterase (AChE), with IC_{50} of 56.75 μM .¹¹⁸

Peptides, namely cyclo-(L-Leu-L-Pro) (329), cyclo-(L-Val-L-Pro) (330) and cyclo-(L-Phe-L-Val) (331), were isolated from *A. sydowii* very active extract ($84.5 \pm 2.2\%$ of acetylcholinesterase inhibition), through using three different media (peptone (12 g L^{-1}) and sucrose (150 g L^{-1}) as sources of nitrogen and carbon, respectively). The three peptides were active as AChE inhibitors with a uniform IC_{50} value of 0.36 ± 0.17 , $\mu\text{mol mL}^{-1}$ for cyclo-(L-Leu-L-Pro) (329) and cyclo-(L-Val-L-Pro) (330), which was approximately similar to the IC_{50} of galanthamine (0.38 ± 0.15 $\mu\text{mol mL}^{-1}$) and IC_{50} value of 1.13 ± 0.32 for cyclo-(L-Phe-L-Val) (331), showing how some changes in culturing conditions can modify the production of bioactive metabolites, which are silent in other conditions of cultivation.¹¹⁹

In vitro UVB protection studies emphasizes DHICA (5,6-dihydroxyindole-2-carboxylic acid) (332) isolated from the marine-derived fungus *Aspergillus nidulans*, significantly protected HaCaT cells from the action of UVB exposure through reducing cell apoptosis, maintaining the cellular integrity, scavenging the generated ROS, and consecutively down-regulating the lipid peroxidation (LPO) and up-regulating the antioxidant enzyme catalase, SOD (superoxide dismutase) and GPx (glutathione peroxidase), respectively. Furthermore, experiments on gelatin zymography, cell cycle arrest analysis, and western blot analysis on TNF- α and COX-2, IHC (Immunohistochemistry) on Bax and Bcl2 (apoptotic markers) verify the protective role of DHICA (332). In addition, *in vivo* evaluations on BALB/c mice were carried out and reproached

with the sunscreen cream with SPF (sun protective factor) of 20. Skin sections analysis of experimental samples discovered an appreciable decline in the thickness of epidermis concerning the mice skin samples DHICA (332) pre-exposed followed by UVB exposure that was compared to control (UVB exposure alone). RT-PCR results on different inflammatory apoptotic markers also proposed that DHICA (332) possess UVB protective potential, suggesting to explore the possible application of DHICA (332), individually as a sun-protective principle for skin care.¹²⁰ All miscellaneous biological activities concerning marine-derived *Aspergillus* metabolites are depicted in Fig. 16, 18 and 19.

Conclusion and future directions

Natural products originating from the marine genus *Aspergillus* exhibited a large chemical diversity and important medicinal values, providing an untapped potential for medications and drug candidates. This marine-inspired genus has been a strong model since its discovery almost 50 years ago as a treasure trove of naturally derived drug candidates. The accumulation of hundreds of marine-derived *Aspergillus* strains worldwide, together with nearly 30 years of research power in both industry and academia, has created a resource enabling the biosynthesis of natural metabolites to be distinguished between closely related ecological strains. This rapprochement has already exposed the dynamics of microbial gene production and will go on to afford insights into the pathways for creating new structural diversity. The idea that novel microbial taxa inhabiting aquatic environments represent a promising origin for natural product exploration has been supported by detailed biochemical studies of the marine-derived genus *Aspergillus*. In aquatic environments, marine-derived *Aspergillus* strains have typically been isolated mainly from marine animals, such as sponges, ascidians and soft corals and sediments. In comparison, there were few samples of talented marine-derived species living in drastic areas. Subsequently, the interest in marine-derived *Aspergillus* species was growing, and became an essential

source of chemical diversity particularly in the 2018 and 2019 (Fig. 20A).

In accordance with chemical diversity, no unique chemical class could be recognized from marine-derived *Aspergillus* spp., predominantly anthracene derivatives, biphenyl derivatives, alkaloids, isoprenoids and butyrolactones (Fig. 20C). Of the about 2000 typical bioactive metabolites from marine-derived *Aspergillus*, 332 have been reported to exhibit different activities (Fig. 1–19, 20B). Most metabolites of marine *Aspergillus* have demonstrated excellent anti-cancer, antibacterial and anti-inflammatory effects (Fig. 20B), mainly ophiopoline, biphenyl derivatives, and alkaloids, respectively (Fig. 21 A–C). Moreover, other bioactivities also have been exhibited by diverse metabolites such as antidiabetic, antiviral, anti-oxidant, antifungal, neuroprotective, antimycobacterial activities, in particular, those belong to the butenolides, xanthenes, biphenyl derivatives, diterpenes, echinulin-related indole-diketopiperazine alkaloids, steroids class of compounds, respectively as predominant bioactive classes (Fig. 21D and Fig. 22 and 23).

The potentially major and most prevalent pathway to drug development from the marine-derived *Aspergillus* is the based cultivation in which the given strains are fermented and the metabolites produced are then recovered. Because of special requirements, which are needed not only for fungal growth but also for the production of secondary metabolites, comprehensive effort is concerned with this approach. Moreover, this cultivation-dependent approach is not capable of unlocking the full biosynthetic ability of certain fungi.

In conclusion, the endless need for new bioactive principles is of substantial importance. Marine-derived *Aspergillus* species have a worthy agenda for novel biologically active compounds discovery, and for this reason, these species are recognized as a productive source of pharmacologically valuable new metabolites. A limitless scope for the discovery of new therapeutic lead scaffolds is thus strongly advocated in the future for the continuous study of marine-derived *Aspergillus* from underexplored environments.

Conflicts of interest

The authors declare there is no conflict of interest.

Funding

Ministry of Education Saudi Arabia funding this work through the project, number IFKSURP-261.

Acknowledgements

The authors extend their appreciation to the Deputyship for Research & Innovation, “Ministry of Education” in Saudi Arabia for funding this research work through the project number IFKSURP-261.

References

- 1 C. Zhao, H. Liu and W. Zhu, *Weishengwu Xuebao*, 2016, **56**, 331–362.
- 2 D. W. Blayney, Q. Zhang, J. Feng, Y. Zhao, I. Bondarenko, I. Vynnychenko, N. Kovalenko, S. Nair, E. Ibrahim, D. P. Udovista, R. Mohanlal, S. Ogenstad, E. Ette, L. Du, L. Huang and Y. K. Shi, *JAMA Oncol.*, 2020, **6**, 1–8.
- 3 B. Huggett, *Nat. Biotechnol.*, 2019, **37**, 1264–1276.
- 4 F. Aqil, M. Zahin, K. A. El Sayed, I. Ahmad, K. Y. Orabi and J. M. Arif, *Drug Chem. Toxicol.*, 2011, **34**, 167–179.
- 5 A. M. S. Mayer and K. R. Gustafson, *Int. J. Cancer*, 2003, **105**, 291–299.
- 6 J. M. Arif, A. A. Al-Hazzani, M. Kunhi and F. Al-Khodairy, *J. Biomed. Biotechnol.*, 2004, **2004**, 93–98.
- 7 B. Haefner, *Drug Discovery Today*, 2003, **8**, 536–544.
- 8 Y. M. Lee, M. J. Kim, H. Li, P. Zhang, B. Bao, K. J. Lee and J. H. Jung, *Mar. Biotechnol.*, 2013, **15**, 499–519.
- 9 J. Yin, C. Zhang, J. Huang, J. Zhang, D. Liu, J. Huang, P. Proksch and W. Lin, *Tetrahedron Lett.*, 2018, **59**, 3157–3160.
- 10 A. K. Vala, B. Sachaniya, D. Dudhagara, H. Z. Panseriya, H. Gosai, R. Rawal and B. P. Dave, *Int. J. Biol. Macromol.*, 2018, **108**, 41–46.
- 11 Z. Wu, D. Li, F. Zeng, Q. Tong, Y. Zheng, J. Liu and Q. Zhou, *Phytochemistry*, 2018, **156**, 159–166.
- 12 W. Feng, C. Chen, S. Mo, C. Qi, J. Gong, X. Li, Q. Zhou, Y. Zhou, D. Li, Y. Lai, H. Zhu, J. Wang and Y. Zhang, *Phytochemistry*, 2019, **164**, 184–191.
- 13 K. Sun, G. Zhu, J. Hao, Y. Wang and W. Zhu, *Tetrahedron*, 2018, **74**, 83–87.
- 14 M. F. Abdelwahab, T. Kurtán, A. Mándi, W. E. G. Müller, M. A. Fouad, M. S. Kamel, Z. Liu, W. Ebrahim, G. Daletos and P. Proksch, *Tetrahedron Lett.*, 2018, **59**, 2647–2652.
- 15 C. Qi, W. Gao, D. Guan, J. Wang and M. Liu, *Bioorg. Med. Chem.*, 2018, **26**, 5903–5910.
- 16 A. M. Elissawy, S. S. Ebada, M. L. Ashour and M. El-neketi, *Phytochem. Lett.*, 2019, **29**, 1–5.
- 17 D. Zhang, W. Yi, H. Ge, Z. Zhang and B. Wu, *Nat. Prod. Res.*, 2019, 1–6.
- 18 Y. Lin, C. Xie, C. Xing, B. Wang, X. Tian, M. Xia, L. Jia, Y. Pan and X. Yang, *Nat. Prod. Res.*, 2019, 1–5.
- 19 M. Elsbaey, A. Sallam, M. El-metwally, M. Nagata and C. Tanaka, *Chem. Biodiversity*, 2019, **16**, e1900237.
- 20 N. D. Luyen, L. M. Huong, T. Thi, H. Ha, L. H. Cuong, D. Thi and H. Yen, *Vietnam J. Chem.*, 2019, **57**, 654–660.
- 21 G. Said, X. Mou, Y. Fang, G. Chen and C. Shao, *Chem. Nat. Prod.*, 2018, **54**, 463–465.
- 22 W. Wang, M. Gao, Z. Luo, Y. Liao, B. Zhang, Z. Shao, F. Li and J. Chen, *Nat. Prod. Res.*, 2019, **33**, 3077–3082.
- 23 Y. Zhang, X. Hou, M. Yu and C. Wang, *Chem. Nat. Compd.*, 2019, **55**, 279–282.
- 24 G. Zhou, X. Chen, X. Zhang, Q. Che, G. Zhang, T. Zhu, Q. Gu and D. Li, *J. Nat. Prod.*, 2020, **83**, 8–13.
- 25 Y. N. Ha, S. Song, B. Orlikova-Boyer, C. Cerella, C. Christov, A. Kijjoa and M. Diederich, *Mar. Drugs*, 2020, **18**, 57.

- 26 A. Zhu, M. Y. Yang, Y. H. Zhang, C. L. Shao, C. Y. Wang, L. D. Hu, F. Cao and H. J. Zhu, *Sci. Rep.*, 2018, **8**, 1–10.
- 27 S. S. Afyattullov, O. I. Zhuravleva, A. S. Antonov, D. V. Berdyshev, M. V. Pivkin, V. A. Denisenko, R. S. Popov, A. V. Gerasimenko, G. von Amsberg, S. A. Dyshlovoy, E. V. Leshchenko and A. N. Yurchenko, *J. Antibiot.*, 2018, **71**, 846–853.
- 28 R. Zhou, X. Liao, H. Li, J. Li, P. Feng, B. X. Zhao and S. Xu, *Front. Chem.*, 2018, **6**, 1–7.
- 29 H. J. Shin, B. K. Choi, P. T. H. Trinh, H. S. Lee, J. S. Kang, T. T. T. Van, H. S. Lee, J. S. Lee, Y. J. Lee and J. Lee, *Mar. Drugs*, 2018, **16**(1), 14.
- 30 S. Buttachon, A. A. Ramos, Â. Inácio, T. Dethoup, L. Gales, M. Lee, P. M. Costa, A. M. S. Silva, N. Sekeroglu, E. Rocha, M. M. M. Pinto, J. A. Pereira and A. Kijjoa, *Mar. Drugs*, 2018, **16**, 1–22.
- 31 G. Yu, G. Wu, Z. Sun, X. Zhang, Q. Che, Q. Gu, T. Zhu, D. Li and G. Zhang, *Mar. Drugs*, 2018, **16**, 14.
- 32 X. Li, W. Ding, P. Wang and J. Xu, *Mar. Drugs*, 2018, **16**, 343.
- 33 Y. N. Wang, Y. H. Mou, Y. Dong, Y. Wu, B. Y. Liu, J. Bai, D. J. Yan, L. Zhang, D. Q. Feng, Y. H. Pei and Y. C. Hu, *Mar. Drugs*, 2018, **16**, 451.
- 34 M. Frank, F. Can Özkaya, W. E. G. Müller, A. Hamacher, M. U. Kassack, W. Lin, Z. Liu and P. Proksch, *Mar. Drugs*, 2019, **17**, 99.
- 35 B. K. Choi, P. T. H. Trinh, H. S. Lee, B. W. Choi, J. S. Kang, N. T. D. Ngoc, T. T. T. Van and H. J. Shin, *Mar. Drugs*, 2019, **17**, 349.
- 36 Y. Fan, Y. Zhou, Y. Du, Y. Wang, P. Fu and W. Zhu, *Mar. Drugs*, 2019, **17**, 400.
- 37 F. Malhão, A. A. Ramos, S. Buttachon, T. Dethoup, A. Kijjoa and E. Rocha, *Mar. Drugs*, 2019, **17**, 448.
- 38 Y.-F. Liu, Y.-F. Yue, L.-X. Feng, H.-J. Zhu and F. Cao, *Mar. Drugs*, 2019, **17**, 550–560.
- 39 Z. X. Li, X. F. Wang, G. W. Ren, X. L. Yuan, N. Deng, G. X. Ji, W. Li and P. Zhang, *Molecules*, 2018, **23**, 2368.
- 40 Y. Tan, B. Yang, X. Lin, X. Luo, X. Pang, L. Tang, Y. Liu, X. Li and X. Zhou, *J. Nat. Prod.*, 2018, **81**, 92–97.
- 41 G. Wu, X. Qi, X. Mo, G. Yu, Q. Wang, T. Zhu, Q. Gu, M. Liu, J. Li and D. Li, *Eur. J. Med. Chem.*, 2018, **148**, 268–278.
- 42 T. Zhu, Z. Lu, J. Fan, L. Wang, G. Zhu, Y. Wang, X. Li, K. Hong, P. Piyachaturawat, A. Chairoungdua and W. Zhu, *J. Nat. Prod.*, 2018, **81**, 2–9.
- 43 X. Du, D. Liu, J. Huang, C. Zhang, P. Proksch and W. Lin, *Fitoterapia*, 2018, **130**, 190–197.
- 44 A. S. Antonov, E. V. Leshchenko, O. I. Zhuravleva, A. Sergey, G. Von Amsberg, R. S. Popov, V. A. Denisenko, N. N. Kirichuk, S. S. Afyattullov, G. Von Amsberg, R. S. Popov, V. A. Denisenko and N. N. Kirichuk, *Nat. Prod. Res.*, 2019, 1–4.
- 45 D. H. Li, T. Han, L. P. Guan, J. Bai, N. Zhao, Z. L. Li, X. Wu and H. M. Hua, *Nat. Prod. Res.*, 2016, **30**, 1116–1122.
- 46 P. K. S. Uchoa, A. T. A. Pimenta, R. Braz-Filho, M. da C. F. de Oliveira, N. N. Saraiva, B. S. F. Rodrigues, L. H. Pfenning, L. M. Abreu, D. V. Wilke, K. G. D. Florêncio and M. A. S. Lima, *Nat. Prod. Res.*, 2017, **31**, 2599–2603.
- 47 X. D. Li, X. Li, X. M. Li, G. M. Xu, P. Zhang, L. H. Meng and B. G. Wang, *Planta Med.*, 2016, **82**, 877–881.
- 48 P. K. S. Uchoa, A. T. A. Pimenta, R. Braz-filho, C. F. De Oliveira, N. N. Saraiva and B. S. F. Rodrigues, *Nat. Prod. Res.*, 2017, **31**, 2599–2603.
- 49 M. M. Lotfy, H. M. Hassan, M. H. Hetta, A. O. El-gendy and R. Mohammed, *Beni-Suef Univ. J. Basic Appl. Sci.*, 2018, **7**, 263–269.
- 50 J. Lin, X. Jiang, X. Liu, C. He, Y. Di, S. Lu, H. Huang, B. Lin, D. Wang and B. Fan, *Fitoterapia*, 2019, **133**, 1–4.
- 51 P. Xu, L. Ding, J. Wei, Q. Li, M. Gui, X. He, D. Su and S. He, *Aquaculture*, 2019, 734670.
- 52 A. N. Shehata, A. A. Abd El Aty, D. A. Darwish, W. A. Abdel Wahab and F. A. Mostafa, *Int. J. Biol. Macromol.*, 2018, **107**, 990–999.
- 53 S. Yang, X. Li, X. Li, H. Li, L. Meng and B. Wang, *Phytochem. Lett.*, 2018, **25**, 191–195.
- 54 H. Li, X. Li, X. Li, S. Yang and B. Wang, *Phytochem. Lett.*, 2019, **32**, 138–142.
- 55 Q. Song, X. Li, X. Hu, X. Li, L. Chi, H. Li and B. Wang, *Phytochem. Lett.*, 2019, **34**, 30–34.
- 56 X. Li, X. Li, X. Li, X. Yin and B. Wang, *Nat. Prod. Res.*, 2019, 1–7.
- 57 P. Corral, F. P. Esposito, P. Tedesco, A. Falco, E. Tortorella, L. Tartaglione, C. Festa, M. V. D. Auria, G. Gnani, G. C. Varese and D. De Pascale, *Mar. Biotechnol.*, 2018, **20**, 502–511.
- 58 L. Guo, F. Zhang, X. Wang, H. Chen, Q. Wang, J. Guo, X. Cao and L. Wang, *3 Biotech*, 2019, **9**, 1–7.
- 59 Y. Ji, W. Chen, T. Shan, B. Sun, P. Yan and W. Jiang, *Chem. Biodiversity*, 2020, **17**, e1900640.
- 60 X. Peng, Y. Wang, T. Zhu and W. Zhu, *Arch. Pharmacol. Res.*, 2018, **41**, 184–191.
- 61 Z. Fei, K. Fan-dong, M. Qing-yun, X. Qing-yi, Z. Li-man, Z. You-xing and G. Lei, *J. Asian Nat. Prod. Res.*, 2019, 1–7.
- 62 G. Said, X. Hou, X. Liu and R. Chao, *Chem. Nat. Compd.*, 2019, **55**, 457–459.
- 63 S. Q. Yang, X. M. Li, X. Li, L. P. Chi and B. G. Wang, *Mar. Drugs*, 2018, **16**, 114.
- 64 A. Zhu, X. W. Zhang, M. Zhang, W. Li, Z. Y. Ma, H. J. Zhu and F. Cao, *Mar. Drugs*, 2018, **16**, 312.
- 65 C. L. An, F. D. Kong, Q. Y. Ma, Q. Y. Xie, J. Z. Yuan, L. M. Zhou, H. F. Dai, Z. F. Yu and Y. X. Zhao, *Mar. Drugs*, 2018, **17**, 468.
- 66 W. Liu, L. Wang, B. Wang, Y. Xu, G. Zhu, M. Lan, W. Zhu and K. Sun, *Mar. Drugs*, 2019, **17**, 6.
- 67 X. Xu, J. Han, Y. Wang, R. Lin, H. Yang, J. Li, S. Wei, S. W. Polyak and F. Song, *Mar. Drugs*, 2019, **17**, 289.
- 68 S. Limbadri, X. Luo, X. Lin, S. Liao, J. Wang, X. Zhou, B. Yang and Y. Liu, *Molecules*, 2018, **23**, 2379.
- 69 Y.-J. Liu, J.-L. Zhang, C. Li, X.-G. Mu, X.-L. Liu, Y.-C. Zhao, P. Zhang, X.-D. Li and X.-X. Zhang, *Molecules*, 2019, **24**, 4596.
- 70 W. Wang, R. Chen, Z. Luo, W. Wang and J. Chen, *Nat. Prod. Res.*, 2018, **32**, 558–563.
- 71 X. Xu, H. Yang, H. Xu, L. Yin, Z. Chen and H. Shen, *Nat. Prod. Res.*, 2018, **32**, 821–825.

- 72 M. Fredimoses, X. Zhou, W. Ai and X. Tian, *Nat. Prod. Res.*, 2015, **29**, 158–162.
- 73 X. Li, X. Li, X. Li, G. Xu, Y. Liu and B. Wang, *Mar. Drugs*, 2018, **16**, 440.
- 74 W. Wang, R. Chen, Z. Luo, W. Wang, J. Chen, W. Wang, R. Chen, Z. Luo, W. Wang and J. Chen, *Nat. Prod. Res.*, 2018, **32**, 558–563.
- 75 M. Chena, K.-L. Wanga, M. Liua, Z.-G. Sheb and C.-Y. Wang, *Chem. Biodiversity*, 2015, **12**, 1398–1406.
- 76 J. Liu, W. Wu, M. Cao, F. Yang and H. Lin, *Nat. Prod. Res.*, 2018, **32**, 1791–1797.
- 77 Z. Liu, Z. Dong, P. Qiu, Q. Wang, J. Yan and Y. Lu, *Steroids*, 2018, **140**, 32–38.
- 78 G. Liao, P. Wu, J. Xue, L. Liu, H. Li and X. Wei, *Fitoterapia*, 2018, **131**, 50–54.
- 79 H. Cui, Y. Liu, T. Li, Z. Zhang, M. Ding, Y. Long and Z. She, *Fitoterapia*, 2018, **124**, 177–181.
- 80 K. Kim, H. Jin, J. Hak, J. Han, Y. Kim and H. Oh, *Neurochem. Int.*, 2018, **113**, 8–22.
- 81 Y. Y. Zhang, Y. Zhang, Y. B. Yao, X. L. Lei and Z. J. Qian, *Mar. Drugs*, 2018, **16**, 202.
- 82 J. T. Liu, W. Wu, M. J. Cao, F. Yang and H. W. Lin, *Nat. Prod. Res.*, 2018, **32**, 1791–1797.
- 83 B. Bin Gu, W. Wu, F. R. Jiao, W. H. Jiao, L. Li, F. Sun, S. P. Wang, F. Yang and H. W. Lin, *Org. Lett.*, 2018, **20**, 7957–7960.
- 84 M. Liu, W. Sun, J. Wang, Y. He, J. Zhang and F. Li, *Bioorg. Chem.*, 2018, **80**, 525–530.
- 85 Y. Tang, Y. Liu, Q. Ruan, M. Zhao, Z. Zhao and H. Cui, *Org. Lett.*, 2019, **22**, 1336–1339.
- 86 B. Bin Gu, F. R. Jiao, W. Wu, W. H. Jiao, L. Li, F. Sun, S. P. Wang, F. Yang and H. W. Lin, *J. Nat. Prod.*, 2018, **81**, 2275–2281.
- 87 H. Li, W. Sun, M. Deng, Q. Zhou, J. Wang, J. Liu, C. Chen, C. Qi, Z. Luo, Y. Xue, H. Zhu and Y. Zhang, *J. Org. Chem.*, 2018, **83**, 8483–8492.
- 88 M. You, L. Liao, S. H. Hong, W. Park, D. I. Kwon, J. Lee, M. Noh, D. Oh, K. Oh and J. Shin, *Mar. Drugs*, 2015, **13**, 1290–1303.
- 89 C. Wang, L. Guo, J. Hao, L. Wang and W. Zhu, *J. Nat. Prod.*, 2016, **79**, 2977–2981.
- 90 K. H. Cho, J. H. Sohn and H. Oh, *Nat. Prod. Res.*, 2018, **32**, 214–221.
- 91 D. Kim, T. M. Ha, J. H. Sohn and J. H. Yim, *Nat. Prod. Res.*, 2018, 1–8.
- 92 Y. Sun, J. Liu, L. Li, C. Gong, S. Wang, F. Yang, H. Hua and H. Lin, *Bioorg. Med. Chem. Lett.*, 2018, **28**, 315–318.
- 93 M. Liu, W. Sun, J. Wang, Y. He, J. Zhang, F. Li, C. Qi, H. Zhu, Y. Xue, Z. Hu and Y. Zhang, *Bioorg. Chem.*, 2018, **80**, 525–530.
- 94 Y. Wu, Y. Chen, X. Huang, Y. Pan, Z. Liu, T. Yan, W. Cao and Z. She, *Mar. Drugs*, 2018, **16**, 1–9.
- 95 Z. Huang, X. Nong, R. Zhe, J. Wang, X. Zhang and S. Qi, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 787–791.
- 96 Y.-Q. Tian, X.-P. Lin, Z. Wang, X.-F. Zhou, X.-C. Qin, K. Kaliyaperumal, T.-Y. Zhang, Z.-C. Tu and Y. Liu, *Molecules*, 2015, **21**, 34.
- 97 J. Peng, X. Zhang, W. Wang, T. Zhu, Q. Gu and D. Li, *Mar. Drugs*, 2016, **14**, 131.
- 98 T. Liang, Y. Fang, J. Zheng and C. Shao, *Chem. Nat. Compd.*, 2018, **54**, 474–476.
- 99 H. H. Kang, H. Bin Zhang, M. J. Zhong, L. Y. Ma, D. S. Liu, W. Z. Liu and H. Ren, *Mar. Drugs*, 2018, **16**, 1–9.
- 100 N. Liu, S. Peng, J. Yang, Z. Cong, X. Lin, S. Liao, B. Yanga, X. Zhoua, X. Zhoub, Y. Liua and J. Wanga, *Fitoterapia*, 2019, **135**, 27–32.
- 101 A. S. Leutou, K. Yun and B. W. Son, *Arch. Pharmacol. Res.*, 2016, **39**, 806–810.
- 102 Z. Wu, Y. Wang, D. Liu, P. Proksch, S. Yu and W. Lin, *Tetrahedron*, 2016, **72**, 50–57.
- 103 A. Muhammad, L. Xiao, M. Xuan, D. Jun-de and Q. Shu-hua, *Nat. Prod. Res.*, 2019, 1–9.
- 104 Q. Zeng, W. Zhong, Y. Chen, Y. Xiang, X. Chen, W. Zhang, S. Zhang and F. Wang, *Nat. Prod. Res.*, 2019, 1–8.
- 105 S. Zou, Z. Wang, J. Wang, G. Wei, W. Wang, Y. Zang, F. Zeng, K. Chen, J. Liu, J. Wang, Z. Luo, Y. Xue, H. Zhu, C. Yin, C. Chen and Y. Zhang, *Fitoterapia*, 2018, **124**, 127–131.
- 106 W. U. Ze-hong, L. I. U. Dong, X. U. Ying, C. Jian-liang and L. I. N. Wen-han, *Chin. J. Nat. Med.*, 2018, **16**, 219–224.
- 107 Z. Yang, K. Kaliaperumal, J. Zhang, Y. Liang, C. Guo, J. Zhang, B. Yang and Y. Liu, *Nat. Prod. Res.*, 2020, 1–8.
- 108 X. D. Li, X. Li, X. M. Li, G. M. Xu, Y. Liu and B. G. Wang, *Mar. Drugs*, 2018, **16**, 440.
- 109 K. Takahashi, K. Sakai, W. Fukasawa, Y. Nagano, S. O. Sakaguchi, A. O. Lima, V. H. Pellizari, M. Iwatsuki, K. Takishita, T. Yoshida, K. Nonaka, K. Fujikura and S. Omura, *J. Antibiot.*, 2018, **71**, 741–744.
- 110 A. N. Yurchenko, O. F. Smetanina, E. V. Ivanets, T. T. Hoai, N. Thi, D. Ngo, O. I. Zhuravleva, A. B. Rasin, A. Sergey, E. S. Menchinskaya, E. A. Pisyagin, G. Von, S. S. Afyattullov, E. A. Yurchenko, A. N. Yurchenko, O. F. Smetanina, E. V. Ivanets, T. Thi, E. S. Menchinskaya, E. A. Pisyagin, G. Von Amsberg and S. S. Afyattullov, *Nat. Prod. Res.*, 2019, 1–6.
- 111 E. A. Yurchenko, E. S. Menchinskaya, E. A. Pisyagin, P. T. H. Trinh, E. V. Ivanets, O. F. Smetanina and A. N. Yurchenko, *Mar. Drugs*, 2018, **16**, 457.
- 112 O. F. Smetanina, A. N. Yurchenko, E. V. G. Ivanets, P. Thi, H. Trinh, A. S. Antonov, S. A. Dyshlovoy, G. Von Amsberg, N. Y. Kim, E. A. Chingizova, E. A. Pisyagin, E. S. Menchinskaya, E. A. Yurchenko, T. T. T. Van and S. S. Afyattullo, *Molecules*, 2020, **25**, 61.
- 113 L. U. O. Xiao-wei, L. I. N. Yun, L. U. Yong-jun, Z. Xue-feng and L. I. U. Yong-hong, *Chin. J. Nat. Med.*, 2019, **17**, 149–154.
- 114 X. Li, Z. Xia, J. Tang, J. Wu, J. Tong, M. Li, J. Ju, H. Chen and L. Wang, *Molecules*, 2017, **22**, 1302.
- 115 G. F. A. Lzd-, Z. Cheng, L. Lou, D. Liu, X. Li, P. Proksch, S. Yin and W. Lin, *J. Nat. Prod.*, 2016, **79**, 2941–2952.
- 116 G. K. Oleinikova, O. I. Zhuravleva, D. V. Berdyshev, I. Natalia, R. S. Popov, V. A. Denisenko, N. N. Kirichuk and S. S. Afyattullov, *Nat. Prod. Res.*, 2019, 1–4.

- 117 A. Ls, L. Huang, L. Ding, X. Li, N. Wang, Y. Yan, M. Yang, W. Cui, C. B. Naman, K. Cheng, W. Zhang, B. Zhang, H. Jin, L. Dak, S. Yip, Y. Chin and K. Li, *Bioorg. Med. Chem. Lett.*, 2019, **29**, 1593–1596.
- 118 W. C. Yang, H. Y. Bao, Y. Y. Liu, Y. Y. Nie, J. M. Yang, P. Z. Hong and Y. Zhang, *Molecules*, 2018, **23**, 2245.
- 119 S. Lima, A. Mendes, G. Franco, A. Ferreira, D. Silva, I. Evódio and J. Aparecida, *Phytochem. Lett.*, 2018, **24**, 39–45.
- 120 S. K. Shanuja, S. Iswarya and A. Gnanamani, *J. Photochem. Photobiol., B*, 2018, **179**, 139–148.